ATE542898T1 - Verfahren zur herstellung von spezifischen bindungspaargliedern - Google Patents

Verfahren zur herstellung von spezifischen bindungspaargliedern

Info

Publication number
ATE542898T1
ATE542898T1 AT06018386T AT06018386T ATE542898T1 AT E542898 T1 ATE542898 T1 AT E542898T1 AT 06018386 T AT06018386 T AT 06018386T AT 06018386 T AT06018386 T AT 06018386T AT E542898 T1 ATE542898 T1 AT E542898T1
Authority
AT
Austria
Prior art keywords
sbp
members
sbp members
component
capsid
Prior art date
Application number
AT06018386T
Other languages
English (en)
Inventor
John Mccafferty
Anthony Richard Pope
Kevin Stuart Johnson
Hendricus Renerus Jacobus Hoogenboom
Andrew David Griffiths
Ronald Henry Jackson
Kaspar Philipp Holliger
James David Marks
Timothy Piers Clackson
David John Chiswell
Gregory Paul Winter
Timothy Peter Bonnert
Original Assignee
Medimmune Ltd
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27516982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE542898(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909024503A external-priority patent/GB9024503D0/en
Priority claimed from GB919104744A external-priority patent/GB9104744D0/en
Priority claimed from GB919110549A external-priority patent/GB9110549D0/en
Application filed by Medimmune Ltd, Medical Res Council filed Critical Medimmune Ltd
Application granted granted Critical
Publication of ATE542898T1 publication Critical patent/ATE542898T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Seal Device For Vehicle (AREA)
AT06018386T 1990-07-10 1991-07-10 Verfahren zur herstellung von spezifischen bindungspaargliedern ATE542898T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB909015198A GB9015198D0 (en) 1990-07-10 1990-07-10 Binding substance
GB909022845A GB9022845D0 (en) 1990-07-10 1990-10-19 Antibodies
GB909024503A GB9024503D0 (en) 1990-11-12 1990-11-12 Binding substances
GB919104744A GB9104744D0 (en) 1991-03-06 1991-03-06 Binding substances
GB919110549A GB9110549D0 (en) 1991-05-15 1991-05-15 Binding substances

Publications (1)

Publication Number Publication Date
ATE542898T1 true ATE542898T1 (de) 2012-02-15

Family

ID=27516982

Family Applications (6)

Application Number Title Priority Date Filing Date
AT04005419T ATE358720T1 (de) 1990-07-10 1991-07-10 Bakteriophagenpartikeln,die dabs präsentieren
AT96112510T ATE212663T1 (de) 1990-07-10 1991-07-10 Methode zur herstellung von filamentösen, antikörper-präsentierenden bakteriophagenpartikeln durch verwendung von phagemiden und die daduch hergestellten bakteriophagenpartikel
AT09001901T ATE447023T1 (de) 1990-07-10 1991-07-10 Verfahren zur herstellung von spezifischen bindungspaargliedern
AT91913039T ATE145237T1 (de) 1990-07-10 1991-07-10 Verfahren zur erzeugung funktioneller, einkettiger fv antikoerper-fragmente auf bakteriophagen-oberflächen
AT97120149T ATE339497T1 (de) 1990-07-10 1991-07-10 Verfahren zur herstellung von spezifischen bindungspaargliedern
AT06018386T ATE542898T1 (de) 1990-07-10 1991-07-10 Verfahren zur herstellung von spezifischen bindungspaargliedern

Family Applications Before (5)

Application Number Title Priority Date Filing Date
AT04005419T ATE358720T1 (de) 1990-07-10 1991-07-10 Bakteriophagenpartikeln,die dabs präsentieren
AT96112510T ATE212663T1 (de) 1990-07-10 1991-07-10 Methode zur herstellung von filamentösen, antikörper-präsentierenden bakteriophagenpartikeln durch verwendung von phagemiden und die daduch hergestellten bakteriophagenpartikel
AT09001901T ATE447023T1 (de) 1990-07-10 1991-07-10 Verfahren zur herstellung von spezifischen bindungspaargliedern
AT91913039T ATE145237T1 (de) 1990-07-10 1991-07-10 Verfahren zur erzeugung funktioneller, einkettiger fv antikoerper-fragmente auf bakteriophagen-oberflächen
AT97120149T ATE339497T1 (de) 1990-07-10 1991-07-10 Verfahren zur herstellung von spezifischen bindungspaargliedern

Country Status (15)

Country Link
US (7) US5969108A (de)
EP (7) EP1754787B1 (de)
JP (1) JP3176917B2 (de)
KR (1) KR100222326B1 (de)
AT (6) ATE358720T1 (de)
AU (1) AU664155B2 (de)
CA (1) CA2086936C (de)
DE (7) DE69133545T2 (de)
DK (5) DK0589877T4 (de)
ES (5) ES2285292T3 (de)
GB (2) GB9015198D0 (de)
GR (1) GR3022126T3 (de)
LU (1) LU91623I2 (de)
NL (1) NL300423I1 (de)
WO (1) WO1992001047A1 (de)

Families Citing this family (2975)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
FI903489A7 (fi) * 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
ES2139598T3 (es) * 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
WO1992006191A1 (en) * 1990-09-28 1992-04-16 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
US6893845B1 (en) 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) * 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) * 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (de) 1991-06-14 2003-11-26 Genentech, Inc. Humanisierter Heregulin Antikörper
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JP3540315B2 (ja) * 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
DE69233408T2 (de) * 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
EP1696031B1 (de) 1991-12-02 2010-04-07 MedImmune Limited Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
EP0656941B1 (de) * 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994005781A1 (en) * 1992-09-04 1994-03-17 The Scripps Research Institute Phagemids coexpressing a surface receptor and a surface heterologous protein
CA2145278C (en) * 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
GB9220808D0 (en) * 1992-10-02 1992-11-18 Medical Res Council Antibody genes
US6936464B1 (en) 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
WO1994018221A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
EP0614989A1 (de) * 1993-02-17 1994-09-14 MorphoSys AG Verfahren für in vivo Selektion von Ligandenbindende Proteine
DE614989T1 (de) * 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US6027884A (en) * 1993-06-17 2000-02-22 The Research Foundation Of The State University Of New York Thermodynamics, design, and use of nucleic acid sequences
DE69414870T2 (de) 1993-09-22 1999-05-12 Medical Research Council, London Antikoerper mit geaenderter zielrichtung
DK145493D0 (da) * 1993-12-23 1993-12-23 Dako As Antistof
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP0859841B1 (de) * 1995-08-18 2002-06-19 MorphoSys AG Protein-/(poly)peptidbibliotheken
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
GB9518731D0 (en) 1995-09-13 1995-11-15 Innes John Centre Flowering genes
ATE455171T1 (de) * 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US7883872B2 (en) * 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US5811381A (en) * 1996-10-10 1998-09-22 Mark A. Emalfarb Cellulase compositions and methods of use
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6497874B1 (en) * 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
DE69842225D1 (de) 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20040241759A1 (en) * 1997-06-16 2004-12-02 Eileen Tozer High throughput screening of libraries
WO1999006587A2 (en) * 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
GB9717192D0 (en) 1997-08-13 1997-10-22 Innes John Centre Innov Ltd Genetic control of plant growth and development
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CN1276830A (zh) * 1997-09-02 2000-12-13 住友制药株式会社 抗乙型肝炎病毒核心蛋白的单链抗体及其基因和含有它们的乙型肝炎治疗药物
GB9718455D0 (en) 1997-09-02 1997-11-05 Mcgregor Duncan P Chimeric binding peptide library screening method
WO1999015897A1 (en) * 1997-09-19 1999-04-01 Chiron Corporation Subtractive protein screening for gene identification
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DE69836823D1 (de) 1997-10-21 2007-02-15 Univ Glasgow Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
ATE393912T1 (de) 1998-02-04 2008-05-15 Invitrogen Corp Microarrays und ihre verwendungen
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
EP0947582A1 (de) * 1998-03-31 1999-10-06 Innogenetics N.V. Eine Polypeptidstruktur zur Verwendung als Gerüst
US7163682B2 (en) 1998-04-13 2007-01-16 The Forsyth Institute Glucan binding protein and glucosyltransferase immunogens
US7056517B2 (en) 1998-04-13 2006-06-06 The Forsyth Institute Glucosyltransferase immunogens
GB2379933B (en) * 1998-05-13 2003-07-09 Domantis Ltd Selection system for phagemids using proteolytically sensitive helper phage
ES2299244T3 (es) * 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
PT1086138E (pt) 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
US6323325B1 (en) 1998-07-23 2001-11-27 The United States Of America As Represented By The Department Of Health And Human Services Agents that bind to and inhibit human cytochrome P450 2A6
US6335428B1 (en) * 1998-07-23 2002-01-01 The United States Of America As Represented By The Department Of Health And Human Services Agents that bind to and inhibit human cytochrome P450 1A2
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
ATE286136T1 (de) * 1998-10-06 2005-01-15 Mark Aaron Emalfarb Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen
US6420110B1 (en) 1998-10-19 2002-07-16 Gpc Biotech, Inc. Methods and reagents for isolating biologically active peptides
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
BR0009323A (pt) 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
EP1169473B1 (de) 1999-04-14 2006-11-22 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Hochsensitiver nachweis von biomolekülen mittels "phage display"
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
WO2000069457A1 (en) 1999-05-15 2000-11-23 University Of California, San Diego Protein a based binding domains with desirable activities
US7163686B1 (en) 1999-05-15 2007-01-16 The Regents Of The University Of California Protein A based binding domains with desirable activities
US20020102613A1 (en) * 1999-05-18 2002-08-01 Hoogenboom Hendricus Renerus Jacobus Mattheus Novel Fab fragment libraries and methods for their use
EP1054018B1 (de) * 1999-05-18 2009-01-28 Dyax Corp. Fab Fragmentbibliotheken und Verfahren für deren Verwendung
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6262265B1 (en) 1999-06-18 2001-07-17 Microgenics Corporation Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
KR20020025990A (ko) 1999-08-23 2002-04-04 나가야마 오사무 에이치엠1.24 항원의 발현 증강제
US7297478B1 (en) 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
WO2001027146A2 (en) 1999-10-12 2001-04-19 Chemocentryx, Inc. Chemokine receptor
US20060073509A1 (en) * 1999-11-18 2006-04-06 Michael Kilpatrick Method for detecting and quantitating multiple subcellular components
CA2392470A1 (en) * 1999-11-26 2001-05-31 Basf Plant Science Gmbh Method for the mutagenesis of nucleotide sequences from plants algae or fungi
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
EP1626056B1 (de) 1999-12-30 2012-03-28 President and Fellows of Harvard College Verfahren und Zusammensetzungen zur Modulierung des Hepatozytenwachstums, der Differenzierung von Plasmazellen oder der Aktivität von T-Zellen durch Modulierung der Aktivität von XBP-1
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
WO2001062908A2 (en) * 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
WO2001062907A1 (fr) 2000-02-22 2001-08-30 Medical & Biological Laboratories Co., Ltd. Bibliotheque d'anticorps
GB2360282A (en) * 2000-03-17 2001-09-19 Bioinvent Int Ab Making and using micro-arrays of biological materials
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ES2531551T3 (es) * 2000-04-17 2015-03-17 Dyax Corp. Métodos para construir bibliotecas de presentación de paquetes genéticos para miembros de una familia diversa de péptido
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20010041349A1 (en) * 2000-04-17 2001-11-15 Andrew Patron Protein expression system arrays and use in biological screening
US7495070B2 (en) * 2000-04-24 2009-02-24 Yale University Protein binding miniature proteins
US7297762B2 (en) * 2000-04-24 2007-11-20 Yale University Modified avian pancreatic polypeptide miniature binding proteins
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
DK1287364T3 (da) 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
DE60141463D1 (de) 2000-06-08 2010-04-15 Immune Disease Inst Inc Methoden und verbindungen zur hemmung immunoglobulin-vermittelter reperfusions-verletzungen
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US20020115068A1 (en) * 2000-06-23 2002-08-22 Ian Tomlinson Matrix screening method
US20020055110A1 (en) * 2000-06-23 2002-05-09 Ian Tomlinson Matrix screening method
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
EP1301532B1 (de) 2000-07-14 2011-02-02 CropDesign N.V. Inhibitoren für cyclin-dependent-kinase von pflanzen
US20020019004A1 (en) * 2000-08-03 2002-02-14 Albert Orfao Method for isolating molecules, cells and other particles which are specifically bound to a large particle
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
GB0022748D0 (en) 2000-09-15 2000-11-01 Allied Therapeutics Ltd Reducing the content of cells in a biological sample
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
WO2002046208A2 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
EP1355939A2 (de) 2000-11-03 2003-10-29 Pestka Biomedical Laboratories, Inc. Interferone, deren verwendungen und zusammensetzungen
NZ526617A (en) 2000-11-28 2004-09-24 Wyeth Corp Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
JP2004526425A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なfkbp核酸およびポリペプチドの発現分析
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1370589B1 (de) 2000-12-05 2006-03-15 Alexion Pharmaceuticals, Inc. Rationell entworfene antikörper
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US20020165149A1 (en) * 2000-12-08 2002-11-07 Kranz David M. Mutated class II major histocompatibility proteins
EP1355919B1 (de) 2000-12-12 2010-11-24 MedImmune, LLC Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
JP4860098B2 (ja) 2000-12-18 2012-01-25 ダイアックス、コープ 遺伝的パッケージの焦点を合わせたライブラリー
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
WO2002060484A1 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
US20020147312A1 (en) * 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
DK1358318T3 (da) * 2001-02-07 2007-01-02 Wilex Ag Hybridomcellelinje G250 og dens anvendelse til frembringelse af monoklonale antistoffer
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
EP1377664A2 (de) 2001-02-23 2004-01-07 DSM IP Assets B.V. Gene, die für proteolytische enzyme von aspargilli kodieren
US20030044406A1 (en) * 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US7795494B2 (en) 2001-03-22 2010-09-14 Abbott Laboratories Transgenic mice expressing antibodies specific for genes of interest and uses thereof
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1383800A4 (de) * 2001-04-02 2004-09-22 Idec Pharma Corp ZUSAMMEN MIT GnTIII EXPRIMIERTE REKOMBINANTE ANTIKÖRPER
EP2388590A1 (de) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
EP1249499A1 (de) * 2001-04-10 2002-10-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zur Bestimmung und Selektion von Molekül-Molekül-Wechselwirkungen
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 血管内皮増殖因子2
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
EP1395274A2 (de) * 2001-05-22 2004-03-10 Duke University Zusammensetzungen und verfahren zur metastasenhemmung
US7132401B2 (en) 2001-05-22 2006-11-07 Merck & Co., Inc. Beta-secretase substrates and uses thereof
US20020197253A1 (en) * 2001-05-22 2002-12-26 Cheek Dennis J. Compositions and methods for promoting or inhibiting NDPK
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
KR20030033007A (ko) * 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
CA2469843A1 (en) * 2001-06-04 2002-12-12 Ikonisys Inc. Method for detecting infectious agents using computer controlled automated image analysis
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
AU2002322388A1 (en) 2001-06-22 2003-01-08 E.I. Du Pont De Nemours And Company Defensin polynucleotides and methods of use
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CA2456470A1 (en) * 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2462531A1 (en) * 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
US20030086929A1 (en) 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase
WO2003035839A2 (en) * 2001-10-24 2003-05-01 Dgi Biotechnologies, Inc. Target specific screening andits use for identifying target binders
WO2003035679A2 (en) 2001-10-25 2003-05-01 Medical Research Council Molecules
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP4723810B2 (ja) 2001-12-03 2011-07-13 アレクシオン ファーマシューティカルズ, インコーポレイテッド ハイブリッド抗体
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003051917A2 (en) 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
JP4323317B2 (ja) * 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) 可変領域配列のクローニング方法
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
AU2003209340A1 (en) * 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
EP1489968B1 (de) * 2002-03-01 2009-02-18 Siemens Healthcare Diagnostics Inc. Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
ATE441107T1 (de) 2002-03-01 2009-09-15 Siemens Healthcare Diagnostics Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von kírperflüssigkeiten
PT1916001E (pt) 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
EP1572149A2 (de) 2002-03-07 2005-09-14 The Forsyth Institute Immunogenität von glucan-bindungsprotein
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
US7745192B2 (en) 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
EP2270049A3 (de) 2002-04-12 2011-03-09 Medimmune, Inc. Rekombinante Anti-Interleukin-9-Antikörper
EP1500665B1 (de) 2002-04-15 2011-06-15 Chugai Seiyaku Kabushiki Kaisha VERFAHREN ZUR HERSTELLUNG VON scDb-BIBLIOTHEKEN
ATE459880T1 (de) 2002-04-17 2010-03-15 Deutsches Krebsforsch Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade.
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
ATE356871T1 (de) * 2002-05-17 2007-04-15 Alligator Bioscience Ab Eine methode zur in vitro molekularen evolution der proteinfunktion
WO2003097082A2 (en) 2002-05-17 2003-11-27 Protein Design Labs Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
CN101684470A (zh) 2002-05-21 2010-03-31 Dsmip资产有限公司 新的磷脂酶及其用途
WO2003102136A2 (en) 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
EP1513879B1 (de) * 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheken synthetischer antikörperphagen
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
US7304128B2 (en) * 2002-06-04 2007-12-04 E.I. Du Pont De Nemours And Company Carbon nanotube binding peptides
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2490804C (en) 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DE60335383D1 (de) 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20040131614A1 (en) 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
ATE469913T1 (de) 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
JP4630663B2 (ja) 2002-08-13 2011-02-09 ハプトゲン リミテッド 抗ラクトンシグナル分子抗体または抗ラクトン由来シグナル分子抗体による感染性細菌症の治療のための方法
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CN1675355A (zh) 2002-08-19 2005-09-28 帝斯曼知识产权资产管理有限公司 新颖的脂肪酶及其用途
EP2311980A1 (de) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
US7455989B2 (en) 2002-08-20 2008-11-25 Yeda Research And Development Co. Ltd. AKAP84 and its use for visualization of biological structures
WO2004019966A1 (ja) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液製剤の安定化方法
CA2496508C (en) 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US8557743B2 (en) 2002-09-05 2013-10-15 Dyax Corp. Display library process
JP5366286B2 (ja) 2002-09-10 2013-12-11 ジェネンコー・インターナショナル・インク 高濃度糖類混合物を用いた遺伝子発現の誘発
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
AU2003291002A1 (en) 2002-11-15 2004-06-15 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004205631A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
AU2004206250B8 (en) * 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
JP2007521249A (ja) 2003-01-24 2007-08-02 エラン ファーマシューティカルズ,インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
RS20050577A (sr) * 2003-01-27 2007-09-21 Biogen Idec Ma Inc., PREPARATI I POSTUPCI ZA TRETIRANjE KANCERA KORIŠĆENjEM IGSF9 I LIV-1
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1947116B1 (de) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
EP2241330A1 (de) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Empfängnisverhütende Verfahren und Zusammensetzungen betreffend proteasomale Störung
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
MXPA05009556A (es) 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
JP2006520597A (ja) 2003-03-20 2006-09-14 ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ 細胞運動性に関する物質および方法
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 il­9 항체 및 그의 용도
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP2365001A3 (de) 2003-05-01 2012-03-28 Imclone LLC Vollständig humane Antikörper, die sich gegen den Wachstumfaktor-1-Rezeptor richten, der dem menschlichen Insulin ähnelt
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP1651162B1 (de) 2003-05-20 2015-10-21 ImmunoGen, Inc. Verbesserte zytotoxische mittel mit neuen maytansinoiden
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US20040248323A1 (en) 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
US20040248109A1 (en) * 2003-06-09 2004-12-09 Lawrence Greenfield Methods for selecting protein binding moieties
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
EP1642971B1 (de) 2003-06-18 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Fucosetransporter
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20050058658A1 (en) * 2003-07-15 2005-03-17 Barros Research Institute Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
CA2532250A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP2007500132A (ja) 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ldcamのアンタゴニストおよびアゴニスト、並びにその使用法
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2128270B1 (de) 2003-08-08 2012-10-03 Genenews Inc. Osteoarthritis-Biomarker und Verwendungen davon
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
EP1660186B1 (de) 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
WO2005034732A2 (en) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2005035548A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
ATE466106T1 (de) 2003-10-10 2010-05-15 Deutsches Krebsforsch Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
ATE534037T1 (de) * 2003-10-15 2011-12-15 Hoffmann La Roche Verwendung des proteins asc als marker für brustkrebs
SI1680140T1 (sl) 2003-10-16 2011-08-31 Imclone Llc Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
EP1983000B1 (de) 2003-11-21 2015-09-02 UCB Biopharma SPRL Verfahren zur Behandlung von multipler Sklerose mittels Hemmung der IL-17-Aktivität
WO2005054860A1 (en) 2003-12-01 2005-06-16 Dako Denmark A/S Methods and compositions for immuno-histochemical detection
WO2005055936A2 (en) * 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
ES2405848T3 (es) * 2003-12-23 2013-06-04 Biokit S.A. Composiciones y métodos para detección de infección patógena
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
EP1737971B1 (de) 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
EP2444805A3 (de) 2004-01-21 2012-06-20 Fujirebio America, Inc. Erkennung von Mesothelin-/Megakaryozyten zur Potenzierung von faktorbezogenen Peptiden in peritonealer Flüssigkeit zur Bewertung des Peritoneum und Peritonealhöhle
GB0401876D0 (en) 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
EP2340850A1 (de) 2004-02-10 2011-07-06 The Regents of the University of Colorado, a Body Corporate Hemmung von Faktor B, dem alternativen Komplement-Pfad und relevante Verfahren
EP2168986A3 (de) 2004-02-19 2010-07-28 Genentech, Inc. Antikörper mit korrigiertem CDR
CA2560066A1 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research, Inc. Natural igm antibodies and inhibitors thereof
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
WO2005095964A2 (en) 2004-03-24 2005-10-13 Tripath Imaging, Inc. Methods and compositions for the detection of cervical disease
EP1786463A4 (de) 2004-03-26 2009-05-20 Human Genome Sciences Inc Antikörper gegen nogo-rezeptor
GB0407008D0 (en) 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
EP1745149A4 (de) 2004-04-15 2008-08-06 Univ Florida Neurale proteine als biomarker für eine verletzung des nervensystems und andere neurale störungen
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
GB0410958D0 (en) 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
BRPI0510909A2 (pt) * 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
ATE505727T1 (de) * 2004-05-26 2011-04-15 Fraunhofer Ges Forschung Isolation allergen-spezifischer immunoglobulin- gene aus humanen b-zellen von atopikern
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP1766014A4 (de) 2004-06-03 2008-12-10 Athlomics Pty Ltd Mittel und verfahren zur diagnose von stress
ES2415665T3 (es) 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
EP2322554A1 (de) 2004-06-30 2011-05-18 Domantis Limited Zusammensetzung die ein anti-TNF-alpha Domainantiköper enthält zur Behandlung von Rheumatoide Arthritis
EP1781680B8 (de) 2004-07-06 2016-05-18 Bioren, LLC Universelle antikörperbibliotheken
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
CN101014365B (zh) 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
JP5014130B2 (ja) 2004-08-02 2012-08-29 ズィナイス オペレーションズ ピーティーワイ.エルティーディー. Vegf−bアンタゴニストを含む癌治療方法
EP1789070B1 (de) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in der neuronalen funktion
US7572600B2 (en) 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
EP1623996A1 (de) * 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verbessertes Verfahren zur Auswahl eines Proteins von einer Bibliothek
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
ITRM20040406A1 (it) * 2004-08-10 2004-11-10 Bait Biotecnologie Applicate Italiane Srl Complesso in grado di rilevare un analita, procedimento per la sua preparazione e usi di esso.
ES2377979T3 (es) * 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
EP1797176A2 (de) * 2004-09-09 2007-06-20 University of Washington All-trans-retinol:all-trans-13,14-dihydroretinol-saturase und verfahren zu ihrer verwendung
FI20041204A0 (fi) 2004-09-16 2004-09-16 Riikka Lund Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン,インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 addl 항체 및 그 용도
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060148104A1 (en) * 2004-10-29 2006-07-06 Massachusetts Institute Of Technology Detection of ion channel or receptor activity
SI1817345T1 (sl) 2004-11-09 2009-10-31 Philogen Spa Protitelesa proti tenascinu-C
EP2377555A3 (de) 2004-11-18 2011-11-23 Imclone LLC Antikörper gegen den vaskulären endothelialen Wachstumsfaktorrezeptor-1
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
EP1819732A2 (de) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Humane monoklonale influenza-m2-protein-antikörper und verfahren zu deren herstellung und verwendung
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
SI1835922T1 (sl) * 2004-12-22 2009-10-31 Merck Serono Sa Kombinacijsko zdravljenje multiple skleroze
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
CA2593212A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
EP1858545A2 (de) 2005-03-04 2007-11-28 Curedm Inc. Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
EP1869192B1 (de) 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
AU2006226192A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
EP2551282A3 (de) 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 sc(Fv)2構造異性体
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディとその使用
US20060269556A1 (en) * 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
PL1874818T3 (pl) 2005-04-22 2011-09-30 Lilly Co Eli Przeciwciała swoiste wobec TGF-beta 1
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
EP1877444A2 (de) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin-antikörper
US7595380B2 (en) 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP3530736A3 (de) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのtnf阻害剤の使用
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
JP2008545712A (ja) 2005-05-25 2008-12-18 キュアーディーエム、インク. ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
CN103505728A (zh) 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
WO2006130374A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
US7989219B2 (en) 2005-05-31 2011-08-02 Canon Kabushiki Kaisha Bispecific capturing molecule
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
JP2006333825A (ja) * 2005-06-03 2006-12-14 Canon Inc 標的物質捕捉用タンパク質の製造方法及びその構成材料の選択方法
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 sc(Fv)2を含有する医薬組成物
ES2547463T3 (es) * 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
WO2007094842A2 (en) 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN103145837A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
JP5142458B2 (ja) * 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN101501215A (zh) 2005-07-07 2009-08-05 阿什洛米克斯控股有限公司 用于诊断内毒素血症的多核苷酸标记基因及它们的表达
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
EP1904652A2 (de) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
DK1915620T3 (da) 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
JP2009502180A (ja) 2005-08-03 2009-01-29 アデレイド リサーチ アンド イノベーション ピーティーワイ リミテッド 多糖シンターゼ
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
NZ594784A (en) 2005-08-18 2013-06-28 Genmab As Therapy with CD4 binding peptides and radiation
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2500353A3 (de) 2005-08-19 2012-10-10 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
SI2447283T1 (sl) 2005-09-07 2015-12-31 Amgen Fremont Inc. Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2007031734A1 (en) * 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
EP1934261B1 (de) 2005-09-26 2014-10-29 Medarex, L.L.C. Humane monoklonale antikörper gegen cd70
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
EP2532677A1 (de) 2005-10-21 2012-12-12 Novartis AG Menschliche Antikörper gegen IL13 und therapeutische Verwendungen
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
US8249814B2 (en) 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
EP2862867A3 (de) 2005-10-25 2015-08-05 The Johns Hopkins University Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
BRPI0619331A2 (pt) 2005-10-26 2011-09-27 Medarex Inc método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto
WO2007051077A2 (en) 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
EP1959979A4 (de) 2005-11-04 2010-01-27 Biogen Idec Inc Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
US20100028358A1 (en) 2005-11-07 2010-02-04 Wolfram Ruf Compositions and Methods for Controlling Tissue Factor Signaling Specificity
EP1957531B1 (de) 2005-11-07 2016-04-13 Genentech, Inc. Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
ATE547709T1 (de) 2005-11-14 2012-03-15 Metamol Theranostics Llc Tumorinvasionsfördernde peptidsequenz
WO2007055378A1 (ja) 2005-11-14 2007-05-18 Cell Signals Inc. 調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007062037A2 (en) * 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類cd134(ox40)之人類單株抗體及其製造及使用方法
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
CA2631615A1 (en) 2005-11-30 2007-04-24 Massachusetts Institute Of Technology Pathogen detection biosensor
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
JP4976412B2 (ja) 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
EA017491B1 (ru) 2005-12-08 2012-12-28 Медарекс, Инк. Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
CA2632628C (en) 2005-12-09 2016-01-19 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
EP1803814A1 (de) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Methode zur Verbesserung der Antikörperselektionskapazität in einer Phagen-Display-Bibliothek
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Erasmus大學醫學中心 對偶基因排除
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP2009524438A (ja) 2006-01-27 2009-07-02 トライパス イメージング インコーポレイテッド 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物
EP2526968A3 (de) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo-Rezeptorantagonisten
US20080038761A1 (en) * 2006-01-30 2008-02-14 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
WO2007120975A2 (en) 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-22(il-22)之抗體及其用途
EP2514824A3 (de) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen
EP2650306A1 (de) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Gm-csf 수용체에 대한 결합 성분
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (de) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
AU2007234733A1 (en) 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
EP2666478A3 (de) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Schuppenflechte
JP5242382B2 (ja) 2006-04-14 2013-07-24 株式会社医学生物学研究所 エフェクター機能を有するポリペプチド変異体
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之c-kit抗體
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
AU2007248559A1 (en) 2006-05-04 2007-11-15 Abmaxis Inc. Cross-species and multi-species display systems
EP2016101A2 (de) * 2006-05-09 2009-01-21 Genentech, Inc. Bindung von polypeptiden mit optimierten gerüsten
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ, エルエルシー インフルエンザウイルスに対する中和抗体
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
ES2544888T3 (es) 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
JP2009544761A (ja) 2006-06-14 2009-12-17 マクロジェニクス,インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
EP2158898A1 (de) 2006-06-23 2010-03-03 Aegis Therapeutics LLC Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
EP2029173B1 (de) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア, 細胞接着分子の発現を調節するための組成物
ES2372709T3 (es) 2006-07-05 2012-01-25 Catalyst Biosciences, Inc. Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
WO2008007755A1 (en) 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
EP2047862B9 (de) 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Mittel zur behandlung von nierenerkrankungen
RU2009107707A (ru) 2006-08-04 2010-09-10 Новартис АГ (CH) СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
KR20090058512A (ko) 2006-08-04 2009-06-09 아스트라제네카 아베 Erbb2에 대한 인간 항체
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
AU2007283463B2 (en) 2006-08-11 2012-04-26 Csl Limited Treatment of pulmonary disease conditions
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−1(sdf−1)に対するモノクローナル抗体
EP2548576B1 (de) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnose von Krebs mittels Anti-Desmoglein-3 Antikörper
CA2661023C (en) 2006-08-18 2017-08-15 Novartis Ag Prlr-specific antibody and uses thereof
US20100011462A1 (en) 2006-08-22 2010-01-14 University Of Copenhagen Flavin monooxygenases and transcription factors involved in glucosinolate biosynthesis
EP2484696B1 (de) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistische hLIGHT-spezifische menschliche monoklonale Antikörper
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
HUE052220T2 (hu) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP2067045B1 (de) 2006-09-28 2020-08-05 The Macfarlane Burnet Institute for Medical Research and Public Health Limited Verfahren zur bestimmung der anzahl an cd4+ t-zellen und kit dafür
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
KR20090069330A (ko) 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
EP2064335A4 (de) 2006-10-16 2011-03-30 Medimmune Llc Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
PL2068922T3 (pl) 2006-10-19 2012-11-30 Csl Ltd Przeciwciała anty-IL-13R alfa1 i ich zastosowania
ES2501947T3 (es) 2006-10-19 2014-10-02 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
AU2007311946A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗hb−egf抗体を有効成分として含む医薬組成物
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP1921142A1 (de) * 2006-11-07 2008-05-14 Cytos Biotechnology AG Auswahl von menschlichen monoklonalen Antikörpern unter Verwendung von eukaryontischem Zell-Display
KR20090088896A (ko) 2006-11-09 2009-08-20 아이알엠 엘엘씨 효현제 trkb 항체 및 그의 용도
US20100247552A1 (en) 2006-11-10 2010-09-30 Massachusetts Institute Of Technology Pak modulators
MX2009005189A (es) 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
EP2514439A1 (de) 2006-11-15 2012-10-24 Functional Genetics, Inc. Anti-TSG101-Antikörper und deren Verwendung bei der Behandlung von Virusinfektionen
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
BRPI0720116B8 (pt) 2006-12-05 2021-07-27 Decode Genetics Ehf método para determinar uma suscetibilidade à arritmia cardíaca ou acidente vascular cerebral em um indivíduo humano, uso de uma sonda de oligonucleotídeo, e, aparelho para determinar um indicador genético para a arritmia cardíaca e/ou acidente vascular cerebral em um indivíduo humano
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
US9862956B2 (en) 2006-12-10 2018-01-09 Danisco Us Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
EP2505651A3 (de) 2006-12-10 2013-01-09 Dyadic International, Inc. Pilzisolate mit reduzierter Proteaseaktivität
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
CA2672581A1 (en) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
EP2099827B1 (de) 2006-12-18 2018-11-21 Genentech, Inc. Antagonistische antikörper gegen notch-3 und ihre verwendung zur prävention und behandlung von notch-3-vermittelten krankheiten
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2586458B1 (de) 2006-12-27 2016-08-24 The Johns Hopkins University Zusammensetzungen und verfahren zur behandlung von entzündungs- und autoimmunerkrankungen
CA2673870A1 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
EP2114983B8 (de) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl-tyrosinkinasehemmer sowie verfahren zu ihrer herstellung und verwendung
EP2522743A3 (de) 2007-02-07 2013-08-07 Decode Genetics EHF. Zum Prostatakrebsrisiko beitragende genetische Varianten
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US8685666B2 (en) * 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
DK2471954T3 (en) 2007-02-21 2016-09-12 Decode Genetics Ehf Susceptibility genetic variants associated with cardiovascular diseases
LT3067066T (lt) 2007-02-23 2019-06-25 Prothena Biosciences Limited Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP3118221B1 (de) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteine
AU2008219972A1 (en) 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
RU2571931C2 (ru) 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2145902A3 (de) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
PT2164868E (pt) 2007-05-04 2015-08-04 Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
PT3072525T (pt) 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
ES2541051T3 (es) * 2007-05-17 2015-07-15 Genentech, Inc. Estructuras cristalinas de fragmentos de neuropilina y complejos neuropilina-anticuerpo
EP2535425A1 (de) 2007-05-25 2012-12-19 Decode Genetics EHF. Genetische varianten auf chr 10q26 als marker zur verwendung bei der risikobeurteilung, diagnose, prognose und behandlung von brustkrebs
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗robo1抗体を含むpet用腫瘍診断剤
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US7709215B2 (en) 2007-06-01 2010-05-04 Cytonics Corporation Method for diagnosing and treating acute joint injury
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
WO2008151819A2 (en) 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
EP2158221B1 (de) 2007-06-21 2018-08-29 MacroGenics, Inc. Kovalente diabodies und deren verwendung
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
CN101784564B (zh) 2007-07-13 2014-07-02 约翰霍普金斯大学 B7-dc变体
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EA017995B1 (ru) 2007-07-25 2013-04-30 Филоджен С.П.А. Антиген, связанный с вариантами рака легкого и лимфомами
EP2174667B1 (de) 2007-07-26 2017-01-04 Osaka University Mittel zur behandlung von augenentzündungen mit interleukin-6-rezeptorhemmer als wirkstoff
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
EP2185719B1 (de) 2007-08-02 2013-11-13 NovImmune SA Rantes-antikörper und verfahren zu ihrer verwendung
CA2693310C (en) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
WO2009020477A1 (en) * 2007-08-06 2009-02-12 Yale University Modified miniature proteins
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル.エル.シー. Hco32およびhco27、ならびに関連実施例
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
MX2010000232A (es) 2007-08-21 2010-06-02 Morphosys Ag Metodos mejorados para la formacion de enlaces disulfuro.
EP2185188B1 (de) 2007-08-22 2014-08-06 Medarex, L.L.C. Ortsspezifische bindung von wirkstoffen oder anderen mitteln an gentechnisch hergestellte antikörper mit c-terminalen erweiterungen
EP2195023B1 (de) 2007-08-29 2018-03-07 Sanofi Humanisierte anti-cxcr5-antikörper, derivate und anwendungsverfahren
PT2193142E (pt) * 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗epha2抗体
SI2769729T1 (sl) 2007-09-04 2019-06-28 Compugen Ltd. Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
WO2009033071A2 (en) * 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) * 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2698390C (en) 2007-09-18 2018-05-22 Dako Denmark A/S A rapid and sensitive method for detection of biological targets
EP2535350B1 (de) 2007-09-26 2018-01-24 UCB Biopharma SPRL Antikörperfusionen mit Doppelspezifität
EP3127921A1 (de) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
BRPI0817482B8 (pt) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
US8470560B2 (en) 2007-10-03 2013-06-25 The United States Of America As Represented By The Secretary Of The Army CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
EP2205971A4 (de) * 2007-10-04 2011-03-30 Bionomics Ltd Endothelzellen-marker und verwendungen davon
CN108130327A (zh) 2007-10-11 2018-06-08 第三共株式会社 靶向破骨细胞相关蛋白Siglec-15的抗体
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
PL2202307T5 (pl) 2007-10-15 2021-10-04 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania przeciwciała
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP3072963B1 (de) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem bronchialkarzinom
KR20100089851A (ko) 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 trkb 항체의 용도
EP2230300A4 (de) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd Polypeptid mit verbesserter effektorfunktion
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
EP2209805B1 (de) 2007-10-30 2017-09-06 Philogen S.p.A. Mit rheumatoider arthritis assoziiertes antigen
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
WO2009059317A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
MX2010004761A (es) 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
CN104109208A (zh) 2007-11-14 2014-10-22 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
CN101918452A (zh) 2007-11-15 2010-12-15 中外制药株式会社 与Anexelekto结合的单克隆抗体及其利用
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
UY31478A1 (es) 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
EP2225275A4 (de) 2007-11-28 2013-04-03 Medimmune Llc Proteinformulierung
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US8697360B2 (en) 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
AU2009203464A1 (en) 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
EP2388323B1 (de) 2008-01-11 2016-04-13 Gene Techno Science Co., Ltd. Humanisierte Anti-9-Integrinantikörper und Verwendungen davon
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
EP2803675A3 (de) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin-Antikörper und Anwendungsverfahren
EP2250201B1 (de) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrantransporter napi2b (slc34a2)-epitop für antikörpertherapie, darauf gerichtete antikörper und zielmolekül für krebstherapie
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
WO2009100110A1 (en) 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2245153A4 (de) * 2008-02-13 2011-06-22 Dyax Corp Verbesserte verfahren zur herstellung spezifischer bindungspaare
CA2714521A1 (en) 2008-02-14 2009-08-20 Decode Genetics Ehf Susceptibility variants for lung cancer
EP2271366A4 (de) 2008-02-28 2012-06-20 3M Innovative Properties Co Antikörper gegen sporen von clostridium difficile und ihre verwendungen
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
UA99339C2 (ru) 2008-03-12 2012-08-10 Имклоун Ллк Антитело, которое специфично связывает человеческий tyrp1
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
NZ601815A (en) 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
NZ588905A (en) 2008-04-01 2012-08-31 Decode Genetics Ehf Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
ES2588194T3 (es) 2008-04-11 2016-10-31 Seattle Genetics, Inc. Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
KR101746861B1 (ko) 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 rgd에 특이적인 인간화된 항체 및 그의 용도
PT2281078E (pt) * 2008-04-24 2015-02-05 Dyax Corp Bibliotecas de pacotes genéticos compreendendo desenhos de novas cdr1, cdr2, e cdr3 de hc e novas cdr1, cr2, e cdr3 de lc
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
US20090269786A1 (en) * 2008-04-25 2009-10-29 The Board Of Trustees Of The University Of Illinois RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
EP2282769A4 (de) 2008-04-29 2012-04-25 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2288381A2 (de) 2008-05-02 2011-03-02 Cancer Research Technology Limited Produkte und verfahren zur stimulation einer immunantwort
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN102089430B (zh) 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
WO2009140684A2 (en) * 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
EP2304439A4 (de) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anti-phospho-akt-antikörper
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
WO2009147695A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
EP2297209A4 (de) 2008-06-03 2012-08-01 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
JP2011524179A (ja) 2008-06-16 2011-09-01 パトリス リミテッド Lm−1抗体、機能性フラグメント、lm−1標的抗原、ならびにそれらを作製および使用するための方法
KR20110038047A (ko) 2008-06-20 2011-04-13 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 산화 LDL/β2GPI복합체에 대한 항체 및 그 용도
CA2729934A1 (en) 2008-07-07 2010-01-14 Decode Genetics Ehf Genetic variants for breast cancer risk assessment
KR20110040886A (ko) 2008-07-08 2011-04-20 아보트 러보러터리즈 프로스타글란딘 e2 결합 단백질 및 이의 용도
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
EP2315779A2 (de) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
MX2011000501A (es) 2008-07-18 2011-05-23 Squibb Bristol Myers Co Composiciones monovalentes para union a cd28 y metodos de uso.
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010010469A2 (en) * 2008-07-25 2010-01-28 Abbott Gmbh & Co. Kg Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
WO2010016806A1 (en) 2008-08-08 2010-02-11 Agency For Science, Technology And Research (A*Star) Vhz for diagnosis and treatment of cancers
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
EP3199630B1 (de) 2008-09-05 2019-05-08 President and Fellows of Harvard College Kontinuierliche gerichtete evolution von proteinen und nukleinsäuren
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
JP5616892B2 (ja) 2008-09-12 2014-10-29 ダコ・デンマーク・エー/エス 前立腺癌バイオマーカー
US20110287026A1 (en) 2008-09-23 2011-11-24 President And Fellows Of Harvard College Sirt4 and uses thereof
WO2010039533A2 (en) 2008-09-23 2010-04-08 Wyeth Methods for predicting production of activating signals by cross-linked binding proteins
JP2012503982A (ja) 2008-09-26 2012-02-16 ワイス・エルエルシー 適合性ディスプレイベクター系
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
WO2010040073A1 (en) 2008-10-03 2010-04-08 Xoma Technology Ltd. Novel triple tag sequences and methods of use thereof
EP2346532B1 (de) * 2008-10-07 2020-10-07 Bracco Suisse SA Target-konstrukt mit einem anti-polymer-antikörper und an diesen bindende mikrovesikel
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
JP2012505900A (ja) 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのigf−ii/igf−iie結合タンパク質の使用
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
CN105646643A (zh) 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
ES2732504T3 (es) 2008-10-29 2019-11-22 Circular Commitment Company Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
RU2481824C2 (ru) 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
KR101683033B1 (ko) 2008-10-31 2016-12-06 얀센 바이오테크 인코포레이티드 톨-유사 수용체 3 길항제
WO2010052288A1 (en) 2008-11-07 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
EP2364368B1 (de) 2008-11-07 2014-01-15 Sequenta, Inc. Verfahren zur überwachung von krankheitszuständen mittels sequenzanalyse
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
DK2189539T4 (en) 2008-11-21 2018-09-17 Chimera Biotec Gmbh Conjugate complexes for analyte detection
AU2009319772A1 (en) 2008-11-26 2010-06-03 Centocor Research & Development, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
MX2011005691A (es) 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
EP2370092A1 (de) 2008-12-03 2011-10-05 Research Development Foundation Modulierung von olfml-3-vermittelter angiogenese
SG171812A1 (en) * 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102307897B (zh) 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
CA2748990A1 (en) 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
EP2379116B1 (de) 2009-01-07 2015-08-26 Philogen S.p.A. Mit endometriose assoziierte antigene
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
CA2749572A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
ES2568509T3 (es) 2009-01-15 2016-04-29 Adaptive Biotechnologies Corporation Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
KR101245929B1 (ko) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 항체 매개된 골질 재생
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
ES2453106T3 (es) 2009-01-26 2014-04-04 Electrophoretics Limited Métodos de diagnóstico y pronóstico en relación con la enfermedad de Alzheimer
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
NZ593905A (en) 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
WO2010093450A2 (en) 2009-02-11 2010-08-19 Ludwing Institute For Cancer Research Ltd. Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
EP2396035A4 (de) 2009-02-12 2012-09-12 Human Genome Sciences Inc Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
SI2881402T1 (sl) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Ekspresija mutantnega ros pri humanem raku jeter
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
JP5721639B2 (ja) 2009-02-19 2015-05-20 ダコ・デンマーク・エー/エス 分子標的の検出のための方法と化合物
EP2401296A1 (de) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalente und/oder multispezifische rankl-bindende konstrukte
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US20110305693A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Anitigen-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
US20100227335A1 (en) 2009-03-05 2010-09-09 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーMedarex, L.L.C. Cadm1に特異的な完全ヒト抗体
WO2010102177A1 (en) 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
EP2405920A1 (de) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue therapie gegen angstzustände
EP2406285B1 (de) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Erzeugung, expression und charakterisierung des humanisierten monoklonalen antikörpers k33n
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
GB0904321D0 (en) 2009-03-12 2009-04-22 Cambridge Entpr Ltd Modulation of T-cell mediated immune responses
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5826635B2 (ja) 2009-03-13 2015-12-02 アラーガン、インコーポレイテッドAllergan,Incorporated 免疫系調節エンドペプチターゼ活性アッセイ
US8420092B2 (en) 2009-03-19 2013-04-16 Ben-Gurion University Of The Negev Research And Development Authority Method of treating diabetes by administering an anti-NKp46 antibody
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
US8883153B2 (en) 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
MA33256B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
EP2414543B1 (de) 2009-04-03 2016-10-12 Decode Genetics EHF Genetische marker zur risikobewertung von vorhofflimmern und apoplexie
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
ES2581488T3 (es) 2009-04-08 2016-09-06 Lipum Ab Nuevos métodos para el tratamiento de enfermedades inflamatorias
EP2377932B1 (de) 2009-04-09 2020-11-18 Daiichi Sankyo Company, Limited Antikörper gegen siglec-15
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
NZ616382A (en) 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
WO2010125566A2 (en) 2009-04-27 2010-11-04 Technion Research And Development Foundation Ltd. Markers for cancer detection
CA2759942A1 (en) 2009-04-27 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
ES2550639T3 (es) 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
ES2725356T3 (es) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
HUE028021T2 (en) 2009-04-29 2016-11-28 Janssen Biotech Inc Pen-like receptor antagonists
AU2010242972B2 (en) 2009-04-29 2015-07-09 Abbvie Biotechnology Ltd Automatic injection device
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
EP2427203B1 (de) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f-antikörper und deren verwendung
EP2270053A1 (de) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
AU2010249470B2 (en) * 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
EP2436397B1 (de) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
EP2261242A1 (de) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
RU2567639C2 (ru) 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
EP2445925A1 (de) 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Proteinaufreinigung mittels präzipitation von caprylsäure (octansäure)
CA2765949C (en) 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
WO2011000543A1 (en) 2009-06-30 2011-01-06 Philochem Ag Murine antibody display library
EP2272979A1 (de) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
CA2766861A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
US8796182B2 (en) 2009-07-10 2014-08-05 Decode Genetics Ehf. Genetic markers associated with risk of diabetes mellitus
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
US9259476B2 (en) 2009-07-31 2016-02-16 Wayne State University Monophosphorylated lipid A derivatives
CN102596220A (zh) 2009-07-31 2012-07-18 韦恩州立大学 单磷酸化的脂质a衍生物
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
US20120282173A1 (en) 2009-08-17 2012-11-08 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP2473523A2 (de) 2009-08-31 2012-07-11 Amplimmune, Inc. Verfahren und zusammensetzungen zur hemmung von transplantatabstossung
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
AU2010291902A1 (en) * 2009-09-14 2012-04-05 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
EP2477656B1 (de) 2009-09-15 2017-03-29 CSL Limited Behandlung neurologischer erkrankungen
WO2011034421A1 (en) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2305717A1 (de) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Hemmung von TNIK zur Behandlung von Darmkrebs
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
US20120178910A1 (en) 2009-09-23 2012-07-12 Medarex, Inc. Cation exchange chromatography (methods)
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US9598692B2 (en) 2009-09-25 2017-03-21 University Of Oslo Multivalent phage display systems and methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US9091691B2 (en) 2009-10-20 2015-07-28 Dako Denmark A/S Immunochemical detection of single target entities
NZ599100A (en) 2009-10-20 2014-07-25 Abbvie Inc Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
WO2011053763A2 (en) 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US8420083B2 (en) * 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP2013509874A (ja) 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
EP2496944A2 (de) 2009-11-05 2012-09-12 Novartis AG Prädiktive biomarker für die progression von fibrose
EP2496604B1 (de) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Antikörper gegen hunde-cd20
EP2499491B1 (de) 2009-11-11 2015-04-01 Gentian AS Immunassay zur untersuchung von assoziierten analyten unterschiedlichen ursprungs
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
EP2325311A1 (de) 2009-11-18 2011-05-25 Pierre Fabre Medicament Neuer Phagenanzeigevektor
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
MX2012006443A (es) 2009-12-09 2012-06-28 Inst Nat Sante Rech Med Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
EP2513148B1 (de) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2-antikörper und ihre verwendung
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
AU2010334809C1 (en) 2009-12-23 2015-02-26 Agenus Inc. Binding members for human cytomegalovirus
WO2011084882A2 (en) 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
US8685524B2 (en) 2010-01-29 2014-04-01 Toray Industries, Inc. Polylactic acid-based resin sheet
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド TNF−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
EP2354245A1 (de) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 als Marker für die hepatische PPAR-Aktivität
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
EP2354244A1 (de) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 als Marker für die leberspezifische Insulinresistenz
US9228171B2 (en) 2010-02-05 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulatory B cells (tBREGS) and their use
NO2535358T3 (de) 2010-02-10 2018-05-19
MX2012009318A (es) 2010-02-10 2012-09-07 Novartis Ag Metodos y compuestos para el crecimiento muscular.
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
EP3178846B1 (de) 2010-02-17 2018-08-22 Cedars-Sinai Medical Center Neuartige phosphorylierung von kardialem troponin i als ein monitor einer kardialen verletzung
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
EP2543730B1 (de) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
US20130004519A1 (en) 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
EP2547359B1 (de) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Hemmer von interaktionen, die beta-integrin-g protein-alpha-untereinheit binden
KR20130031247A (ko) 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자(ngf) 항체 조성물
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
PL2552961T3 (pl) 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
JP6002659B2 (ja) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトcd27に結合する抗体およびその使用
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP2561076A1 (de) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation von xrn1
EP2380909A1 (de) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An Brustkrebs beteiligtes Protein PTK-7
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
WO2011140254A1 (en) 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
TWI500427B (zh) 2010-05-14 2015-09-21 Abbvie Inc Il-1結合蛋白
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
US9169329B2 (en) 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
MX2012014080A (es) 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
WO2012047324A2 (en) 2010-06-10 2012-04-12 President And Fellows Of Harvard College Systems and methods for amplification and phage display
CN103201290B (zh) 2010-06-14 2016-09-28 莱克拉生物医学股份公司 S100a4抗体及其治疗用途
BR112012032206A2 (pt) 2010-06-16 2016-10-04 Abbvie Inc comparações de amostras de proteínas
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
EP2588107A1 (de) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Kombination aus einem cmet-hemmer und einem antikörper gegen hgf und/oder cmet
WO2012004565A1 (en) 2010-07-06 2012-01-12 Robert White Cancer biomarker brf1
JP2013533746A (ja) 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ, インコーポレイテッド 抗ron抗体
WO2012004631A2 (en) 2010-07-07 2012-01-12 Tubitak Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr)
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
EP2591000B1 (de) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
NZ605449A (en) 2010-07-09 2015-03-27 Genentech Inc Anti-neuropilin antibodies and methods of use
JP2013539453A (ja) 2010-07-09 2013-10-24 エクセリクシス, インク. 癌の治療のためのキナーゼ阻害物質の組み合わせ
US20130115227A1 (en) 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
AU2011283646B2 (en) 2010-07-30 2015-07-09 Novartis Ag Fibronectin cradle molecules and libraries thereof
EP2601609B1 (de) 2010-08-02 2017-05-17 Population Bio, Inc. Zusammensetzungen und verfahren zur erkennung der verursachenden mutationen in genetischen erkrankungen
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
US20140072983A1 (en) 2010-08-10 2014-03-13 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Fc領域を含むモノマーポリペプチド及び使用方法
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
MX2013001843A (es) 2010-08-17 2013-06-28 Stichting Katholieke Univ Un metodo novedoso para el diagnostico de fiebre q usando una prueba inmunologica celular.
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
ME02637B (de) 2010-08-20 2017-06-20 Novartis Ag Antikörper für den epidermalen wachstumsfaktorrezeptor 3 (her 3)
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CA2809568C (en) 2010-09-01 2019-06-11 Genzyme Corporation Treatment of myocardial infarction using tgf - beta antagonists
WO2012028703A1 (en) 2010-09-02 2012-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of the progression of cancer
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
WO2012034039A2 (en) 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
CA2810909A1 (en) 2010-09-20 2012-03-29 Abbvie Inc. Purification of antibodies using simulated moving bed chromatography
CA2811678C (en) 2010-09-21 2019-10-01 Stichting Katholieke Universiteit Novel method for diagnosing lyme disease using a cellular immunological test
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2622091B1 (de) 2010-09-23 2019-03-13 Precision Biologics, Inc. Peptidomimetika gegen darm- und bauchspeicheldrüsenkrebs
US20120077691A1 (en) 2010-09-24 2012-03-29 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
EP2621950A4 (de) 2010-09-27 2015-09-02 Janssen Biotech Inc Antikörper zur bindung von humanem kollagen ii
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
US9005907B2 (en) 2010-10-01 2015-04-14 St. Jude Children's Research Hospital Methods and compositions for typing molecular subgroups of medulloblastoma
US8525237B1 (en) 2010-10-04 2013-09-03 The Regents Of The University Of California Electrically conductive polymer nanowires with incorporated viruses
EP2625203A1 (de) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
PH12013500703A1 (en) 2010-10-13 2013-05-20 Janssen Biotech Inc Human oncostatin m antibodies and methods of use
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
WO2012054077A2 (en) 2010-10-19 2012-04-26 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
JP6121906B2 (ja) 2010-10-22 2017-04-26 シアトル ジェネティクス,インコーポレーテッド アウリスタチン系抗体薬物複合体とPI3K−AKTmTOR経路インヒビターの間の相乗効果
AU2011323784A1 (en) 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
EP3722808B1 (de) 2010-10-25 2024-09-11 Biogen MA Inc. Verfahren zur bestimmung von unterschieden in einer alpha-4-integrin-aktivität durch korrelation von unterschieden in svcam- und/oder smadcam-ebenen
SI2634194T1 (sl) 2010-10-29 2018-11-30 Perseus Proteomics Inc. Anti-cdh3 protitelo, ki ima visoko kapaciteto internalizacije
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
CA2816763A1 (en) 2010-11-05 2012-05-10 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
CN103201627B (zh) 2010-11-08 2016-10-12 丹麦达科有限公司 组织学样品中单个靶标分子的定量
EP2640366A2 (de) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
EP2640738A1 (de) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antimykotische wirkstoffe
WO2012068106A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2640831A1 (de) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
EP2640742B1 (de) 2010-11-19 2018-08-15 MorphoSys AG Eine sammlung von antikörpersequenzen und deren verwendungen
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
EP2643316A2 (de) 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepine als p13k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
CA2817161C (en) 2010-12-06 2019-04-02 Dako Denmark A/S Combined histological stain
PT3156420T (pt) 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
EP2465928A1 (de) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Behandlung von Th17-vermittelten Krankheiten
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
BR112013015508B1 (pt) 2010-12-20 2022-04-05 Medimmune Limited Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
EP3202903B1 (de) 2010-12-22 2020-02-12 President and Fellows of Harvard College Kontinuierliche gerichtete evolution
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
EP2659269B1 (de) 2010-12-23 2016-10-26 Roche Diagniostics GmbH Erkennung von posttranslational modifiziertem polypeptid durch ein bivalentes bindungsmolekül
CA2817455C (en) 2010-12-23 2019-04-16 F. Hoffmann-La Roche Ag Detection of a polypeptide dimer by a bivalent binding agent
CN103384681B (zh) 2010-12-23 2018-05-18 霍夫曼-拉罗奇有限公司 结合剂
US20140038842A1 (en) 2010-12-28 2014-02-06 Xoma Technology Cell surface display using pdz domains
US9598499B2 (en) 2010-12-30 2017-03-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antigen binding formats for use in therapeutic treatments or diagnostic assays
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
PH12013501435B1 (en) 2011-01-14 2019-02-01 UCB Biopharma SRL Antibody molecules which bind il-17a and il-17f
EP3252076B1 (de) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostische verwendung von antikörpern gegen das protein ror-1
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
SG192119A1 (en) 2011-01-24 2013-08-30 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012106615A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
GB201102189D0 (en) 2011-02-08 2011-03-23 King S College London Materials and methods relating to cardiovascular imaging
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
WO2012110824A1 (en) 2011-02-18 2012-08-23 Astrazeneca Ab Binding agents with specificity for a nucleic acid modification
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
EP2680925B1 (de) 2011-03-02 2019-11-20 Berg LLC Interrogatorische zellbasierte assays und verwendung derselben
CN103502274B (zh) 2011-03-03 2016-01-06 埃派斯进有限公司 抗-il-6受体抗体及其使用方法
CA2865487A1 (en) 2011-03-07 2012-09-13 Paula J. Bates Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
AU2012225310B2 (en) 2011-03-09 2017-08-03 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
US8609818B2 (en) 2011-03-10 2013-12-17 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
EP2698431B1 (de) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Aufrechterhaltung antigenbindender moleküle im blutplasma und verfahren zur modifizierung einer immunogenität
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
US9777332B2 (en) 2011-03-31 2017-10-03 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
US20140186340A1 (en) 2011-04-08 2014-07-03 Gilead Biologics, Inc. Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
CA2832565A1 (en) 2011-04-08 2012-10-11 Biogen Idec Ma Inc. Biomarkers predictive of therapeutic responsiveness to ifn.beta. and uses thereof
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
RU2623161C2 (ru) 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
EP2700652B1 (de) 2011-04-18 2018-12-19 The University of Tokyo Diagnose und behandlung von krebs mittels anti-itm2a-antikörpern
CN103597089B (zh) 2011-04-19 2017-04-12 丹麦达科有限公司 用于酶介导的信号放大的方法
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2703486B1 (de) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3-antikörper
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
GB201108272D0 (en) 2011-05-17 2011-06-29 Cambridge Entpr Ltd Methods relating to HCMV infected cells
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US9067997B2 (en) 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
SG195196A1 (en) 2011-05-27 2013-12-30 Dutalys Dual targeting
US20140255405A1 (en) 2011-05-27 2014-09-11 Dutalys Removal of Monomeric Targets
BR112013030352B1 (pt) 2011-06-02 2020-05-19 Dyax Corp. anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
EP2714735B1 (de) 2011-06-03 2021-07-21 XOMA Technology Ltd. Tgf-beta-spezifische antikörper
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP2717911A1 (de) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
EP2718324A1 (de) 2011-06-10 2014-04-16 Corimmun GmbH Bindende verbindungen gegen menschlichen 1-adrenorezeptor (1-ar) und ihre anwendung zur messung von auto-anti-a1-ar-antikörpern
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
EP2720721B1 (de) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 als zielmolekül für therapeutische antikörper bei der behandlung von krebs
EP2721070A1 (de) 2011-06-17 2014-04-23 Harris, Adrian, L. Verfahren zur verbesserung des ansprechverhaltens auf strahlung in der tumortherapie mit anti-dll4-antikörpern
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
EP4350345A3 (de) 2011-06-23 2024-07-24 Ablynx N.V. Verfahren zur vorhersage, erkennung und reduzierung von aspezifischer proteininterferenz in tests mit variablen immunglobulin-einzeldomänen
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP3363813A1 (de) 2011-06-23 2018-08-22 Ablynx NV Verfahren für vorhersage, nachweis und verringerung von aspezifischer proteininterferenz bei tests mit variablen immunglobulin-einzeldomänen
JP2014527036A (ja) 2011-06-27 2014-10-09 ザ ジャクソン ラボラトリー 癌および自己免疫疾患の処置のための方法および組成物
US9447178B2 (en) 2011-06-28 2016-09-20 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
EA031181B1 (ru) 2011-06-28 2018-11-30 Оксфорд Байотерепьютикс Лтд. Антитело, которое специфически связывается с bst1, или его антигенсвязывающий фрагмент, нуклеиновые кислоты, кодирующие его цепи, клетка-хозяин, способ получения этого антитела и применение для лечения рака и воспалительных заболеваний
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
EP2726503B1 (de) 2011-06-30 2019-09-04 Compugen Ltd. Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen
JP6472999B2 (ja) 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
EP2548891A1 (de) 2011-07-18 2013-01-23 Universiteit Maastricht Humaner monoklonaler Antikörper gegen die Gamma-Untereinheit des Acetylcholin-Rezeptors zur Verwendung bei der Behandlung von Rhabdomyosarkom
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
PH12014500220A1 (en) 2011-07-27 2019-03-22 Glaxo Group Ltd Anti-vegf single variable domains fused to fc domains
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
HUE039009T2 (hu) 2011-08-05 2018-12-28 Res Found Dev Javított eljárások és készítmények Olfml3-mediált angiogenesis modulálására
WO2013025446A2 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ddr1抗体
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
KR101886983B1 (ko) 2011-08-23 2018-08-08 로슈 글리카트 아게 2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
EP2753356B1 (de) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antikörper und ihre verwendungen
MX362457B (es) 2011-09-12 2019-01-18 Janssen Biotech Inc Antagonistas del receptor tipo toll 3.
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP2771349B1 (de) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
EP2758075B1 (de) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenzavirus-impfstoffe und verwendungen davon
EP2759551B1 (de) 2011-09-21 2019-05-22 Fujirebio Inc. Antikörper die an einen affinitätskomplex binden der 25oh-vitamin d2 oder d3 und einen dagegen gerichteten antikörper enthält
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Vegf/dll4結合劑類及彼等之用途
ES2762179T3 (es) 2011-09-26 2020-05-22 Philogen Spa Terapia de combinación de inmunocitocinas
KR102366029B1 (ko) 2011-09-30 2022-02-23 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20250078601A (ko) 2011-09-30 2025-06-02 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
CN107287660A (zh) 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
EP2765192A4 (de) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigenbindendes molekül zur herstellung eines abstands zwischen einem plasma und einem antigen mit einer saccharidkettenrezeptor-bindenden domäne
WO2013052933A2 (en) 2011-10-06 2013-04-11 The Board Of Trustees Of The University Of Illinois Myosin binding protein-c for use in methods relating to diastolic heart failure
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
CN103906767A (zh) 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
HK1201565A1 (en) 2011-10-21 2015-09-04 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
EP3603671A3 (de) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Krebstammzellenspezifisches molekül
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
HK1201855A1 (en) 2011-11-01 2015-09-11 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773664A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49-antikörper
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
US9441042B2 (en) 2011-11-02 2016-09-13 Apexigen, Inc. Anti-KDR antibodies and methods of use
JP6301258B2 (ja) 2011-11-03 2018-03-28 トライパス イメージング インコーポレイテッド 免疫染色試料を調製するための方法および構成物
EP2773779B1 (de) 2011-11-04 2020-10-14 Population Bio, Inc. Verfahren und zusammensetzungen zur diagnose, prognose und behandlung neurologischer erkrankungen
WO2013070615A1 (en) 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
MX2014005570A (es) 2011-11-08 2014-05-30 Pfizer El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
PL3553084T3 (pl) 2011-11-16 2023-04-17 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan
US9140696B2 (en) 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
BR112014011670B1 (pt) 2011-11-16 2021-05-25 Adrenomed Ag anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica
HRP20191771T1 (hr) 2011-11-16 2019-12-27 Adrenomed Ag Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije
ES2494190T3 (es) 2011-11-16 2014-09-15 Adrenomed Ag Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
HRP20190122T1 (hr) 2011-11-16 2019-03-08 Adrenomed Ag Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
US20140017174A1 (en) 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP2788382A2 (de) 2011-12-05 2014-10-15 Novartis AG Antikörper für epidermalen wachstumsfaktor-rezeptor 3 (her3) gegen domäne ii von her3
EP3388535B1 (de) 2011-12-09 2021-03-24 Adaptive Biotechnologies Corporation Diagnose von lymphoid-malignomen und nachweis von minimaler resterkrankung
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
CN104136462B (zh) 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
MX357708B (es) 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
CA2859665C (en) 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
EP3539982B1 (de) 2011-12-23 2025-02-19 Pfizer Inc. Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
KR20190120401A (ko) 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
CN104159922B (zh) 2012-01-10 2018-03-02 比奥根Ma公司 对转运治疗性分子穿过血脑屏障的增强
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
WO2013113615A1 (en) 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
AU2013214172A1 (en) 2012-02-03 2014-08-14 Medimmune Limited Process for reducing antibody aggregate levels and antibodies produced thereby
ME03512B (de) 2012-02-06 2020-04-20 Inhibrx Inc Cd47-antikörper und verfahren zur verwendung davon
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP4624490A3 (de) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modifizierte fc-region eines antikörpers
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
AU2013216863B2 (en) 2012-02-10 2018-09-06 Seagen Inc. Detection and treatment of CD30+ cancers
WO2013116903A1 (en) 2012-02-10 2013-08-15 Phylogica Limited Methods for the characterisation of interaction sites on target proteins
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー/エス 骨髄細胞で発現されるトリガー受容体1(trem−1)に結合し、それを遮断する抗体
US20150201588A1 (en) 2012-02-22 2015-07-23 Amgen Inc. Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
US10077478B2 (en) 2012-03-05 2018-09-18 Adaptive Biotechnologies Corp. Determining paired immune receptor chains from frequency matched subunits
JO3787B1 (ar) 2012-03-15 2021-01-31 Janssen Biotech Inc أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
AU2013232114B2 (en) 2012-03-15 2018-10-18 Omeros Corporation Composition and method for diversification of target sequences
WO2013140393A1 (en) 2012-03-21 2013-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peptides derived from the d1 - domain of nkp46
CA2866185C (en) 2012-03-23 2021-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
ES2678211T3 (es) 2012-03-27 2018-08-09 Ventana Medical Systems, Inc. Conjugados de señalización y procedimientos de uso
WO2013148232A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
JPWO2013147212A1 (ja) 2012-03-30 2015-12-14 第一三共株式会社 新規抗Siglec−15抗体
BR112014024537A2 (pt) 2012-04-02 2017-08-08 Berg Llc métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
AU2013247645B2 (en) 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
BR112014025898A2 (pt) 2012-04-17 2017-11-07 Mayo Found Medical Education & Res anticorpos humanos e sequências de ligação específica, para uso em acidente vascular cerebral e isquemia ou condições isquêmicas
WO2013158859A1 (en) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
IN2014DN07799A (de) 2012-04-27 2015-05-15 Daiichi Sankyo Co Ltd
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
PT2831276T (pt) 2012-05-08 2016-07-26 Adaptive Biotechnologies Corp Composições e método para medição e calibração do viés de amplificação em reações pcr multiplex
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
JP6122948B2 (ja) 2012-05-15 2017-04-26 モルフォテック, インコーポレイテッド 胃癌の治療のための方法
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
TW201348247A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質a親和性層析之非人類抗體之新穎純化
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
SG11201408330XA (en) 2012-05-24 2015-01-29 Mountgate Group Ltd Compositions and methods related to prevention and treatment of rabies infection
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
JPWO2013180201A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
MX2014014951A (es) 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
EP4310191A3 (de) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigenbindendes molekül mit modifizierter fc-region
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Fc-영역 접합체의 제조 방법 및 그의 용도
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
US10048253B2 (en) 2012-06-28 2018-08-14 Ucb Biopharma Sprl Method for identifying compounds of therapeutic interest
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
PL4019041T3 (pl) 2012-07-13 2023-05-08 The Trustees Of The University Of Pennsylvania Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP3613765B1 (de) 2012-08-03 2024-10-02 Dana-Farber Cancer Institute, Inc. Antikörper gegen das abstossende wegweisermolekül b (rgmb)
PL3434695T3 (pl) 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
WO2014023709A1 (en) 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9645151B2 (en) 2012-08-17 2017-05-09 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
HK1211208A1 (zh) 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
TR201900694T4 (tr) 2012-08-23 2019-02-21 Agensys Inc 158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスFcγRII特異的Fc抗体
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP2890836B1 (de) 2012-08-31 2019-07-17 The Scripps Research Institute Verfahren im zusammenhang mit modulatoren von eukaryotischen zellen
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
WO2014039860A2 (en) 2012-09-07 2014-03-13 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating dnmt1 inhibitor activity
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
NO2760138T3 (de) 2012-10-01 2018-08-04
EP2904111B1 (de) 2012-10-01 2017-12-06 Adaptive Biotechnologies Corporation Immunkompetenzbeurteilung durch adaptive immunrezeptordiversität und klonalitätscharakterisierung
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
AU2013325443B2 (en) * 2012-10-03 2019-01-31 Livtech, Inc. Anti-hDlk-1 antibody having an anti-tumor activity in vivo
EP2903629B1 (de) 2012-10-03 2019-07-10 Philogen S.p.A. Antikörperkonjugat zur verwendung bei der behandlung von entzündlichen darmerkrankungen
EP2904089A4 (de) 2012-10-04 2016-05-25 Immunogen Inc Verwendung einer pvdf-membran zur reinigung von konjugaten aus zellbindendem mittel und zytotoxikum
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
MX2015004436A (es) 2012-10-09 2015-06-24 Biogen Idec Inc Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
WO2014059251A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
KR102308915B1 (ko) 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체
EP2909606B1 (de) 2012-10-17 2023-12-06 University Of Maryland Vorrichtung und verfahren zur verwendung der vorrichtung für den nachweis von aminoazidopathien
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP2910573B1 (de) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat
CA2888345C (en) 2012-10-24 2020-04-21 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
EP2914628A1 (de) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin Antikörper mit bindung von cd269 (bcma) zur behandlung von plasmazellenkrankheiten wie multiplem myelom und autoimmunerkrankungen
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
EP4223770A3 (de) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Neuartige fusionsmoleküle und verwendungen davon
HK1214521A1 (zh) 2012-11-05 2016-07-29 Genzyme Corporation 用於治療蛋白質病的組合物和方法
EP2914621B1 (de) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Neuartige ntrk1-fusionsmoleküle und verwendungen davon
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
DK2918603T3 (en) 2012-11-08 2018-10-15 Univ Miyazaki ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
BR122020023058B1 (pt) 2012-12-10 2023-12-05 Biogen Ma Inc Ácido nucleico isolado ou ácidos nucleicos
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
EP2934581B1 (de) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenzavirus-impfstoffe und verwendungen davon
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン,エルエルシー 抗h7cr抗体
AU2013202668B2 (en) 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
EP3336104A1 (de) 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanisierte monoklonale antikörper und verfahren zur verwendung zur diagnose und behandlung von darm- und pankreaskrebs
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
FR3004184B1 (fr) 2013-02-26 2016-03-18 Agronomique Inst Nat Rech Anticorps anti-gluten desamide et utilisations.
JP6416793B2 (ja) 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド 結核のバイオマーカー及びその使用
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
HK1219423A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
WO2014142646A1 (en) 2013-03-13 2014-09-18 Stichting Katholieke Universiteit Q-fever diagnostic
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
CA2902789A1 (en) 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
MX362075B (es) 2013-03-14 2019-01-07 Abbott Lab Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
CN105189551B (zh) 2013-03-14 2021-03-05 埃派斯进有限公司 抗-rankl抗体及其使用方法
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
BR112015017307A2 (pt) 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TW201519904A (zh) 2013-03-15 2015-06-01 Abbvie Inc 抗體藥物結合物(adc)之純化
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
CN105358575B (zh) 2013-03-15 2020-09-22 詹森生物科技公司 干扰素α和ω抗体拮抗剂
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP2970489A2 (de) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25-antikörper und deren verwendungen
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
HK1219044A1 (zh) 2013-03-15 2017-03-24 艾伯维德国有限责任两合公司 抗egfr抗体药物偶联物制剂
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
WO2014147153A1 (en) 2013-03-20 2014-09-25 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
US9499621B2 (en) 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
GB201307501D0 (en) 2013-04-25 2013-06-12 Univ Aberdeen Anti-fungal antibody molecules and uses thereof
JP2016524697A (ja) 2013-05-02 2016-08-18 スティッチング カソリーケ ウニベルシテイトStichting Katholieke Universiteit 個人化医療
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
CA2912526C (en) 2013-05-16 2021-09-14 Kyoto University Method for determining prognosis of cancer
GB201309178D0 (en) 2013-05-21 2013-07-03 Ucl Business Plc Enzyme and uses thereof
AU2014268298B2 (en) 2013-05-24 2019-01-17 Medlmmune, Llc Anti-B7-H5 antibodies and their uses
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
EP3003390B1 (de) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54-antikörper und verwendungen davon
EP3003372B1 (de) 2013-06-07 2019-10-09 Duke University Inhibitoren des komplementfaktors h
EP3009518B1 (de) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Verfahren zur vorhersage einer posttherapeutischen prognose von patienten mit schubförmig remittierender multipler sklerose (rrms) und verfahren zur bestimmung der anwendbarkeit der neuartigen therapie
CA2914924A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US20160159919A1 (en) 2013-06-24 2016-06-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding Adenocarcinoma
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
JP6450381B2 (ja) 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性mic中和モノクローナル抗体
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
AR097161A1 (es) 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
MX371455B (es) 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
WO2015022658A2 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
PL3036320T5 (pl) 2013-08-19 2024-06-10 Biogen Ma Inc. Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
CN105764526B (zh) 2013-08-26 2020-12-15 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス, インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
WO2015034052A1 (ja) 2013-09-05 2015-03-12 国立大学法人 宮崎大学 ヒトインテグリンa6b4と特異的に反応する抗体
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
TWI673063B (zh) 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白c抗體之出血性疾病的治療
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3049521B1 (de) 2013-09-25 2019-03-06 Cornell University Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
CA2925897A1 (en) 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
MX2016003617A (es) * 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
EP3470081A1 (de) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6463744B2 (ja) 2013-10-08 2019-02-06 イミュノジェン, インコーポレイテッド 抗folr1免疫抱合体投薬レジメン
CN105792844B (zh) 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
EP3733868A3 (de) 2013-10-28 2021-01-13 DOTS Technology Corp. Allergennachweis
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
US9840555B2 (en) 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
SMT202100473T1 (it) 2013-11-06 2021-09-14 Janssen Biotech Inc Anticorpi anti-ccl17
US20160272673A1 (en) 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of dvd-igs
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
EP2891722B1 (de) 2013-11-12 2018-10-10 Population Bio, Inc. Verfahren und Zusammensetzungen zur Diagnose, Prognose und Behandlung von Endometriose
GB201320061D0 (en) 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
KR102283408B1 (ko) 2013-11-15 2021-07-29 앵스티띠 파스퇴르 플라스모듐 팔시파룸 아르테미시닌 내성의 분자 마커
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US9309314B2 (en) 2013-12-03 2016-04-12 Agency For Science, Technology And Research (A*Star) Polypeptides, nucleic acids and uses thereof
TWI702316B (zh) 2013-12-04 2020-08-21 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
CN105980405A (zh) 2013-12-08 2016-09-28 派特塞尔有限公司 Hiv抗原和抗体及其组合物、方法和用途
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
CN109908017A (zh) 2013-12-19 2019-06-21 高露洁-棕榄公司 口腔护理组合物
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EP2960252A1 (de) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase zur Behandlung von Immunosuppression
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬
US10654933B2 (en) 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
AU2015206788B2 (en) 2014-01-14 2019-10-24 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L for treatment and prevention of cancer
EP3097196B1 (de) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negativauswahl und stringenzmodulation in systemen der kontinuierlichen evolution
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
US11648335B2 (en) 2014-01-31 2023-05-16 Wake Forest University Health Sciences Organ/tissue decellularization, framework maintenance and recellularization
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ, インコーポレイテッド デングウイルスに対する抗体分子およびその使用
EP3107576A4 (de) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3-antikörper und arzneimittelkonjugate zur verwendung in melanomen
JP6417421B2 (ja) 2014-02-28 2018-11-07 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 荷電連結体及び共役体のためのその使用
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2941612A1 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
EP3116906A1 (de) 2014-03-12 2017-01-18 Prothena Biosciences Limited Für lg1-3 spezifische anti-laminin4-antikörper
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
DK3122869T3 (da) 2014-03-24 2019-09-09 Biogen Ma Inc Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
WO2015150900A2 (en) 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
CA2944456C (en) 2014-03-31 2023-10-31 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
WO2015161301A1 (en) * 2014-04-17 2015-10-22 University Of Maryland, College Park Device and methods of using device for detection of aminoacidopathies
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
JP6792454B2 (ja) 2014-04-25 2020-11-25 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. アルファ−フェトプロテイン(afp)を操作するための方法
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
ES2899754T3 (es) 2014-05-02 2022-03-14 Medimmune Ltd Moduladores de canales iónicos y usos de los mismos
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン,エルエルシー 新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
MX394895B (es) 2014-06-03 2025-03-24 Xbiotech Inc Composiciones útiles para el tratamiento de infecciones por staphylococcus aureus.
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
EP3154579A1 (de) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research Neue behandlung gegen das influenzavirus
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
EP3157535A1 (de) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
WO2015200790A2 (en) 2014-06-26 2015-12-30 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
WO2016011035A2 (en) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
CA2956385A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
EA201790336A1 (ru) 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EP3180359A1 (de) 2014-08-14 2017-06-21 Novartis AG Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor
EP3712171A1 (de) 2014-08-19 2020-09-23 Novartis AG Behandlung von krebs mit einem chimären cd123-antigenrezeptor
EP3185004A4 (de) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur messung der viskosität einer proteinlösung
US10961298B2 (en) 2014-08-21 2021-03-30 The Government Of The United States, Represented By The Secretary Of The Army Monoclonal antibodies for treatment of microbial infections
EP3189057A1 (de) 2014-09-03 2017-07-12 ImmunoGen, Inc. Zytotoxische benzodiazepin-derivate
CR20170111A (es) 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
CA2996445A1 (en) 2014-09-05 2016-03-10 Eli Hatchwell Methods and compositions for inhibiting and treating neurological conditions
US10442863B2 (en) 2014-09-08 2019-10-15 Lutana Gmbh Construct for the delivery of a molecule into the cytoplasm of a cell
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EP3191126B1 (de) 2014-09-13 2020-05-13 Novartis AG Kombinationstherapien aus alk-hemmern
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3200822B1 (de) 2014-09-30 2021-04-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Bindungsmoleküle, insbesondere antikörper die sich an l1cam (cd171) binden
RU2021125449A (ru) 2014-10-01 2021-09-16 Медиммьюн Лимитед Антитела к тикагрелору и способы применения
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3207146B1 (de) 2014-10-15 2021-09-29 Amgen Inc. Promotor und regulatorische elemente zur verbesserten expression von heterologen genen in wirtszellen
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
EP3207128B1 (de) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Zwitterionische butyrylcholinesterasepolymerkonjugate
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10738078B2 (en) 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
PL3215527T3 (pl) 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
WO2016073963A1 (en) 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
EP3789403A1 (de) 2014-11-11 2021-03-10 MedImmune Limited Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
ES2788979T3 (es) 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
WO2016081423A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
JP6788586B2 (ja) 2014-11-19 2020-11-25 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Hnlを用いる診断方法
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
RU2017123942A (ru) 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
EP3229844B1 (de) 2014-12-09 2020-03-04 AbbVie Inc. Antikörper-wirkstoff-konjugate mit zelldurchlässigen bcl-xl-inhibitoren
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
EP3233912B1 (de) 2014-12-19 2021-05-19 Regenesance B.V. Antikörper zur bindung von humanem c6 und verwendungen davon
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3789039A1 (de) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
EP3250609A4 (de) 2015-01-26 2018-07-11 The University of Chicago Il13ra-alpha-2-bindende wirkstoffe und verwendung davon bei der krebsbehandlung
EP3250611B1 (de) 2015-01-26 2021-04-21 The University of Chicago Car-t-zellen zur erkennung krebsspezifischer il 13r-alpha2
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2016126488A1 (en) 2015-02-02 2016-08-11 Sea Lane Biotechnologies, Llc Anti-surrogate light chain antibodies
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
WO2016130539A2 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
US10494425B2 (en) * 2015-02-24 2019-12-03 Rpeptide, Llc Anti-amyloid-beta antibodies
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
WO2016144917A1 (en) 2015-03-10 2016-09-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
BR112017018365A2 (pt) 2015-03-13 2018-04-10 Bristol-Myers Squibb Company uso de lavagens alcalinas durante cromatografia para remoção de impurezas
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US20180105555A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran for protein purification
US20180105554A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran sulfate to enhance protein a affinity chromatography
EP3274724A1 (de) 2015-03-25 2018-01-31 Alexion Pharmaceuticals, Inc. Verfahren zur messung der proteaseaktivität von faktor d des alternativen komplementweges
EP3274468B1 (de) 2015-03-25 2019-02-20 Alexion Pharmaceuticals, Inc. Verfahren zur bestimmung der c3- und c5- konvertase protease-aktivität im alternativen komplement-pfad
EP3273994B1 (de) 2015-03-27 2021-12-01 University of Southern California Car-t-zelltherapie gegen lhr zur behandlung von soliden tumoren
EP3277706A1 (de) 2015-03-31 2018-02-07 VHsquared Limited Polypeptid mit immunglobulinkettenvariabler domäne mit bindung an clostridium-difficile-toxin b
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
MX387295B (es) 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3277719B1 (de) 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptide
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
US10125198B2 (en) 2015-04-17 2018-11-13 Distributed Bio, Inc. Method for mass humanization of non-human antibodies
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
US10954515B2 (en) 2015-04-21 2021-03-23 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting ZNF555
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CA2983293C (en) 2015-04-24 2023-06-20 The Regents Of The University Of California Modulators of ror1-ror2 binding
KR20170140318A (ko) 2015-04-29 2017-12-20 리제너론 파마슈티칼스 인코포레이티드 진행성 골화성 섬유이형성증의 치료
US10814012B2 (en) 2015-04-29 2020-10-27 University Of South Australia Compositions and methods for administering antibodies
US11685773B2 (en) 2015-04-30 2023-06-27 Abcheck S.R.O. Method for mass humanization of rabbit antibodies
EA201792442A1 (ru) 2015-05-06 2018-06-29 Янссен Байотек, Инк. Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
EP3292152A1 (de) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40-antikörper und verfahren zur verwendung davon
US10900975B2 (en) 2015-05-12 2021-01-26 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods of epitope binning and antibody profiling
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
ES3063952T3 (en) 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
EP3095465A1 (de) 2015-05-19 2016-11-23 U3 Pharma GmbH Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP6851322B2 (ja) 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗cd40抗体およびその使用
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CA2987992A1 (en) 2015-06-04 2016-12-08 University Of Southern California Lym-1 and lym-2 targeted car cell immunotherapy
SG11201707815RA (en) 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3307772B1 (de) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta-3-spezifische antikörper und verfahren sowie verwendungen davon
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
EP3722314A1 (de) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
JP7021955B2 (ja) 2015-06-24 2022-03-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
EP3313441B1 (de) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immunmodulation und behandlung von soliden tumoren mit spezifisch an cd38 bindenden antikörpern
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (de) 2015-07-29 2018-06-06 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen pd-1
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
EP3331914A1 (de) 2015-08-03 2018-06-13 Novartis AG Verfahren zur behandlung von fgf21-vermittelten erkrankungen
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
JP2018532693A (ja) 2015-08-06 2018-11-08 ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
EP3152570A1 (de) 2015-08-06 2017-04-12 Yaya Diagnostics GmbH Vorrichtung und verfahren zur erkennung von zielen
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
EP3341415B1 (de) 2015-08-28 2021-03-24 H. Hoffnabb-La Roche Ag Anti-hypusin-antikörper und verwendungen davon
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
EP3842457A1 (de) 2015-09-09 2021-06-30 Novartis AG Moleküle zur bindung von thymus-stroma-lymphopoietin (tslp) und verfahren zur verwendung der moleküle
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
CN108348780A (zh) 2015-09-10 2018-07-31 贝克顿·迪金森公司 用作用于环磷酰胺和异环磷酰胺的免疫分析的免疫原和分析缀合物的环磷酰胺类似物
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック, インコーポレイテッド 抗vegf抗体の最適化変異体
JP7054924B2 (ja) 2015-09-23 2022-04-15 サイトイミューン セラピューティクス, インコーポレイテッド 免疫療法のためのflt3指向car細胞
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
PE20181367A1 (es) 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356407B1 (de) 2015-10-02 2021-11-03 F. Hoffmann-La Roche AG Bispezifische anti-cd19xcd3-t-zell-aktivierende antigenbindende moleküle
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ceaxcd3 t細胞活性化抗原結合分子
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
US20170096485A1 (en) 2015-10-02 2017-04-06 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
WO2017055388A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
EP3368157B1 (de) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
MX391162B (es) 2015-10-30 2025-03-21 Galaxy Biotech Llc Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
ITUB20155272A1 (it) 2015-11-02 2017-05-02 Scuola Normale Superiore Intracellular antibody
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
PL3374398T3 (pl) 2015-11-10 2020-08-24 Medimmune, Llc Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (de) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur verbesserung der humoralen immunreaktion
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
WO2017084078A1 (en) 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
JP2019501124A (ja) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗huLRRC15抗体薬物コンジュゲート及びその使用方法
EP3383909B1 (de) 2015-11-30 2020-06-17 AbbVie Inc. Anti-hulrrc15-antikörper-wirkstoff-konjugate und verfahren zu deren verwendung
EP3383920B1 (de) 2015-11-30 2024-01-10 The Regents of the University of California Freisetzung von tumorspezifischer nutzlast und immunaktivierung mit einem menschlichen antikörper gegen hochspezifisches tumorzellenoberflächenantigen
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス, インコーポレイテッド グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
CA3007646A1 (en) 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
WO2017097889A1 (en) 2015-12-10 2017-06-15 Katholieke Universiteit Leuven Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
CN108697794A (zh) 2015-12-17 2018-10-23 诺华股份有限公司 C-met抑制剂和抗pd-1抗体分子的组合及其用途
KR20180087430A (ko) 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
TW201731872A (zh) 2015-12-18 2017-09-16 諾華公司 標靶CD32b之抗體及其使用方法
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2017118761A1 (en) 2016-01-08 2017-07-13 Iontas Ltd Binding members with altered diversity scaffold domains
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
AU2017224122B2 (en) 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CN116063494A (zh) 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ,インコーポレーテッド Ilt7結合分子及びその使用方法
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
EP3431102A4 (de) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha Zellschadeninduzierendes therapeutisches arzneimittel zur verwendung in der krebstherapie
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
AR107893A1 (es) 2016-03-15 2018-06-28 Astrazeneca Ab TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
BR112018068000A2 (pt) 2016-03-16 2019-02-05 Merrimack Pharmaceuticals Inc composições de nanolipossomas de geração de docetaxel direcionados ao receptor a2 de efrina (epha2)
EP3429631A1 (de) 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Behandlung von ephrin-rezeptor a2 (epha2)-positivem krebs mit gezielten docetaxelerzeugenden nanoliposomzusammensetzungen
EP3219727B1 (de) 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf-alpha-antikörper und funktionale fragmente davon
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
IL261793B2 (en) 2016-03-17 2025-04-01 Numab Therapeutics AG ANTI-TNFALPHA ANTIBODIES AND THEIR FUNCTIONAL PARTS
EA039323B1 (ru) 2016-03-17 2022-01-13 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
PT3219726T (pt) 2016-03-17 2020-12-15 Tillotts Pharma Ag Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2017162587A1 (en) 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
EP3433274A1 (de) 2016-03-25 2019-01-30 Visterra, Inc. Formulierung von antikörpermolekülen gegen das denguevirus
EP3231813A1 (de) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
CN109195991B (zh) 2016-03-29 2023-10-31 斯特库比股份有限公司 对糖基化pd-l1特异的双重功能抗体及其使用方法
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
EP3440208B1 (de) 2016-04-06 2020-09-16 Zumutor Biologics, Inc. Vektoren zur klonung und expression von proteinen, verfahren und anwendungen davon
KR102611444B1 (ko) 2016-04-08 2023-12-06 지엘바이오, 인크. 플렉틴-1 결합 항체 및 그의 용도
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
IL262472B2 (en) 2016-04-21 2024-12-01 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitors for use in treating diseases related to necrosis
JP7103950B2 (ja) 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Alk7結合性タンパク質及びその使用
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
EP3243836A1 (de) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
EP3455254B1 (de) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und einem tenascin-bindungsteil
EP3243832A1 (de) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
SG11201809642TA (en) 2016-05-16 2018-11-29 Baxalta Inc Anti-factor ix padua antibodies
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
SMT202100721T1 (it) 2016-05-27 2022-01-10 Abbvie Biotherapeutics Inc Anticorpi anti-cd40 e loro usi
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
WO2017201731A1 (en) 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3464371B1 (de) 2016-06-06 2026-07-29 City of Hope Gegen baff-r gerichtete chimäre antigenrezeptor-modifizierte t-zellen und verwendungen davon
US11136405B2 (en) 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
US12048718B2 (en) 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
EP3471767A4 (de) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenzavirus-hämagglutinin-proteine und verwendungen davon
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3475700A4 (de) 2016-06-26 2020-03-04 Gennova Biopharmaceuticals Limited Antikörper-phagendisplay-bibliothek
US11390661B2 (en) 2016-06-27 2022-07-19 Aicuris Anti-Infective Cures Gmbh HCMV entry inhibitors
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
EP3478714A2 (de) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin-antikörper
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
US20190227082A1 (en) 2016-07-06 2019-07-25 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
CN109716136B (zh) 2016-07-08 2023-09-22 斯弗因高泰克有限公司 肾上腺髓质素用于评估急性心力衰竭患者的充血
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP3484455A2 (de) 2016-07-15 2019-05-22 Novartis AG Behandlung und prävention von zytokin-freisetzungssyndrom unter verwendung eines chimären antigenrezeptors in kombination mit einem kinasehemmer
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US10478497B2 (en) 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
JP2019531332A (ja) 2016-07-22 2019-10-31 ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) Trem2切断モジュレーター及びその使用
US11312745B2 (en) 2016-07-22 2022-04-26 Amgen Inc. Methods of purifying Fc-containing proteins
MA45715A (fr) 2016-07-25 2019-05-29 Biogen Ma Inc Anticorps anti-hspa5 (grp78) et leurs utilisations
EP3491022B1 (de) 2016-07-29 2025-09-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
CN118530358A (zh) 2016-08-01 2024-08-23 佐马美国有限公司 甲状旁腺激素受体1(pth1r)抗体和其用途
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
AR109279A1 (es) 2016-08-03 2018-11-14 Achaogen Inc Anticuerpos anti plazomicina y métodos de uso de los mismos
BR112019002039A2 (pt) 2016-08-05 2019-05-07 Medimmune, Llc anticorpos anti-o2 e uso dos mesmos
EP3497120A1 (de) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Manipulierte antikörper und andere fc-domänen-haltige moleküle mit verbesserten agonismus- und effektorfunktionen
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
JP2019530646A (ja) 2016-08-12 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company タンパク質精製法
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
CA3036564A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
CA3036714A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
WO2018066626A1 (ja) 2016-10-07 2018-04-12 第一三共株式会社 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
CA3039686A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018083238A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py792-ddr1 antibodies
WO2018083235A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py513-ddr1 antibodies
WO2018083240A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py796-ddr1 antibodies
WO2018083237A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Operations Inc. Novel anti-py520-ddr1 antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3535294B1 (de) 2016-11-07 2025-02-12 Neuracle Science Co., Ltd. Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US11103592B2 (en) 2016-11-09 2021-08-31 Philogen S.P.A. IL2 and TNF mutant immunoconjugates
EP3538551A4 (de) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. Cd46-specifische effektorzellen und verwendungen davon
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
AU2017356317A1 (en) 2016-11-14 2019-05-30 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク,インコーポレーテツド 抗il23特異的抗体で乾癬を治療する方法
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
AU2017363309A1 (en) 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
UY37523A (es) 2016-12-15 2018-07-31 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
KR20190120174A (ko) 2016-12-16 2019-10-23 아드레노메드 아게 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
EP3339324A1 (de) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 標的化4-1bb(cd137)アゴニストとの併用療法
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CN118126180A (zh) 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
IL315727A (en) 2016-12-23 2024-11-01 Visterra Inc Binding polypeptides and methods for their preparation
EA201991552A1 (ru) 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела
CN110382530A (zh) 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
HRP20230308T1 (hr) 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
EP3565845A4 (de) 2017-01-06 2020-10-07 Biosion, Inc. Erbb2-antikörper und deren verwendungen
TW201833140A (zh) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
CN110312530A (zh) 2017-01-13 2019-10-08 中央研究院 用以治疗心肌梗塞的可重复装载的水胶系统
WO2018130661A1 (en) 2017-01-13 2018-07-19 Academia Sinica Reloadable hydrogel system for treating brain conditions
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR102607101B1 (ko) 2017-01-26 2023-11-29 제트엘아이피 홀딩 리미티드 Cd47 항원 결합 유닛 및 그것의 사용
EP3574012A1 (de) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispezifische her2- und cd3-bindende moleküle
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US11623945B2 (en) 2017-02-06 2023-04-11 The United States Of America, As Represented By The Secretary Of Agriculture Immunostimulating compositions and uses therefore
TW201837174A (zh) 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗gprc5d抗體及包含該抗體之分子
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
IL298414B2 (en) 2017-02-28 2024-12-01 Immunogen Inc Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
EP3589650A1 (de) 2017-03-02 2020-01-08 Novartis AG Manipulierte heterodimere proteine
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
EP3599843A4 (de) 2017-03-24 2021-01-13 The Regents of the University of California Proteoglycan-irregularitäten in abnormalen fibroblasten und darauf basierende therapien
KR102628323B1 (ko) 2017-03-24 2024-01-22 노바르티스 아게 심장질환 예방 및 치료 방법
EP3604340A4 (de) 2017-03-24 2021-01-06 Zenyaku Kogyo Co., Ltd Anti-igm/b-zelloberflächenantigen-bispezifischer antikörper
WO2018178076A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
US11359005B2 (en) 2017-03-30 2022-06-14 The Johns Hopkins University Supramolecular high affinity protein-binding system for purification of biomacromolecules
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
PE20200010A1 (es) 2017-04-03 2020-01-06 Hoffmann La Roche Anticuerpos que se unen a steap-1
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3609915A1 (de) 2017-04-12 2020-02-19 Pfizer Inc Antikörper mit bedingter affinität und verfahren zur verwendung dafür
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
EP3610268B1 (de) 2017-04-15 2025-09-24 Abbott Laboratories Verfahren zur unterstützung der diagnose und der bestimmung von traumatischen gehirnschäden bei menschen mithilfe frühen biomarkern
EP3612563A1 (de) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3612556B8 (de) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Verbesserte lamp konstrukte
EP4328241A3 (de) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispezifische moleküle mit einer nichtimmunglobulin-heterodimerisierungsdomäne und verwendungen davon
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222433A2 (en) 2017-05-30 2018-12-06 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
CN111010867B (zh) 2017-05-30 2023-05-12 俄克拉何马大学董事会 抗双皮层蛋白样激酶1抗体及其使用方法
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
EP3630836A1 (de) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200014379A (ko) 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
US10995149B2 (en) 2017-06-05 2021-05-04 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
EP3634999A1 (de) 2017-06-07 2020-04-15 Philogen S.p.A. Gefässendothelwachstumsfaktor-/antifibronectin-antikörper-fusionsproteine
ES3000510T3 (en) 2017-06-09 2025-02-28 Providence Health & Services Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3645042A4 (de) 2017-06-26 2021-03-17 Bio-Techne Corporation Hybridom-klone, monoklonale antikörper gegen vsig-4 und verfahren zur herstellung und verwendung
BR112019027729A2 (pt) 2017-06-27 2020-08-18 Neuracle Science Co., Ltd anticorpos anti-fam19a5 e seus usos
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
EP3645564A1 (de) 2017-06-28 2020-05-06 Novartis AG Verfahren zur prävention und behandlung von harninkontinenz
US20200115446A1 (en) 2017-06-30 2020-04-16 National University Corporation Hokkaido University Pediatric osteoporosis drug that does not cause growth disorder
EP3649474A1 (de) 2017-07-03 2020-05-13 Abbott Laboratories Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
SG10201913147WA (en) 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
US20230331827A1 (en) 2017-07-12 2023-10-19 Maxion Therapeutics Limited Potassium channel inhibitors
ES3065893T3 (en) 2017-07-13 2026-05-08 Hoffmann La Roche New binding agent and assay for pivka
KR102787394B1 (ko) 2017-07-14 2025-03-26 화이자 인크. MAdCAM에 대한 항체
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
EP3658581A1 (de) 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper und peptide zur behandlung von erkrankungen im zusammenhang mit hcmv
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CA3071234A1 (en) 2017-07-27 2019-01-31 Daiichi Sankyo Company, Limited Anti-cd147 antibody
EP3658583A1 (de) 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp-komplex-spezifische inhibitoren von tgf-beta 1 und verwendungen davon
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
JP7379323B2 (ja) 2017-08-18 2023-11-14 ザ・ジョンズ・ホプキンス・ユニバーシティ タンパク質精製のための超分子フィラメント集合体
CA3073125A1 (en) 2017-08-18 2019-02-21 Cambridge Enterprise Limited Modular binding proteins
CA3072859A1 (en) 2017-08-23 2019-02-28 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinscht Chimeric antigen receptor and car-t cells that bind cxcr5
US12060553B2 (en) 2017-08-25 2024-08-13 President And Fellows Of Harvard College Evolution of BoNT peptidases
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
CA3074317C (en) 2017-08-25 2024-06-18 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
USD859683S1 (en) 2017-09-21 2019-09-10 Becton, Dickinson And Company Collection device
JP7223749B2 (ja) 2017-09-21 2023-02-16 ベクトン・ディキンソン・アンド・カンパニー 危険汚染物質の試験における高ダイナミックレンジの分析器
EP3684944B1 (de) 2017-09-21 2025-01-01 Becton, Dickinson and Company Kit zur probenahme von gefährlichen schadstoffen und schnelltest
CN111107939B (zh) 2017-09-21 2022-04-12 贝克顿·迪金森公司 引导有害污染物样品的收集的系统和模板及使用其的方法
US20220227854A1 (en) 2017-09-25 2022-07-21 Adrenomed Ag Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
EP3688165A4 (de) 2017-09-25 2021-09-29 Nant Holdings IP, LLC Validierung der präsentation von neoepitopen
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
KR20240017986A (ko) 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
EP3461841B1 (de) 2017-10-02 2019-09-11 Certest Biotec, S.L. Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
AU2018344859A1 (en) 2017-10-04 2020-04-30 Hesperix SA Articles and methods directed to personalized therapy of cancer
BR112020006860A2 (pt) 2017-10-05 2020-10-20 Daiichi Sankyo Company, Limited composição para depleção de células t citotóxicas
EP3693013A4 (de) 2017-10-06 2021-06-30 Ono Pharmaceutical Co., Ltd. Bispezifischer antikörper
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
MX2020004072A (es) 2017-10-18 2020-07-28 Adrenomed Ag Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
KR20200072507A (ko) 2017-10-19 2020-06-22 데비오팜 인터네셔날 에스 에이 암 치료를 위한 조합 제품
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3697809A1 (de) 2017-10-20 2020-08-26 Institut Curie Für rush angepasste dap10/12-basierte cars
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
KR102835427B1 (ko) 2017-10-25 2025-07-21 4틴4 파마슈티컬스 게엠베하 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
TW201922294A (zh) 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
PE20210844A1 (es) 2017-11-01 2021-05-10 Hoffmann La Roche Contorsbodies 2 + biespecificos
EP3704155A2 (de) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Kombinationstherapie mit gezielten ox40-agonisten
AU2018358804A1 (en) 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
EP3713961A2 (de) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
AU2018374283B2 (en) 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
EP3717682A4 (de) 2017-11-30 2021-09-01 University of Delhi, South Campus Antikörperfragmentbibliothek und verwendungen davon
IL275077B2 (en) 2017-12-06 2025-02-01 Magenta Therapeutics Inc Dosing regimens for mobilization of hematopoietic stem and progenitor cells.
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス,インコーポレーテッド 多重特異性分子及びその使用
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング, インコーポレイテッド 抗フリズルド抗体及び使用方法
EP3502139A1 (de) 2017-12-19 2019-06-26 Philogen S.p.A. Antikörper gegen tumorantigene
EP3502140A1 (de) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
GB201721600D0 (en) 2017-12-21 2018-02-07 Plant Bioscience Ltd Metabolic engineering
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
US11466077B2 (en) 2018-01-05 2022-10-11 Ac Immune Sa Misfolded TDP-43 binding molecules
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Pac1抗体及びその使用
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル-マイヤーズ スクイブ カンパニー Tim3に対する抗体およびその使用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
KR102717599B1 (ko) 2018-02-08 2024-10-14 스핑고텍 게엠베하 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
CA3091646A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
EP3752195A4 (de) 2018-02-14 2021-11-17 Viela Bio, Inc. Antikörper gegen felinen mcdonough-sarkom(fms)-ähnlichen tyrosinkinase-3-rezeptorliganden (flt3l) und verwendungen davon zur behandlung von autoimmun- und entzündungskrankheiten
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
EP3530282A1 (de) 2018-02-27 2019-08-28 Diaccurate Therapeutische verfahren
EP3759125A4 (de) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-btnl2 und immuncheckpoint-blockierungsreagenzien
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN111836643A (zh) 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗PHF-Tau抗體及其用途
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク,インコーポレーテツド 抗il-23特異的抗体を用いたクローン病の治療方法
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
PL3765489T3 (pl) 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
BR112020018235A2 (pt) 2018-03-14 2020-12-29 F. Hoffmann-La Roche Ag Métodos para gerar uma biblioteca de polinucleotídeos, bibliotecas de polinucleotídeos, uso de uma biblioteca, método para gerar uma biblioteca de anticorpos e método de seleção de um anticorpo
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
EP3765517A1 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
CN111971300B (zh) 2018-03-14 2024-10-29 豪夫迈·罗氏有限公司 新颖的抗-肌钙蛋白t抗体
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
KR20200131846A (ko) 2018-03-14 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 항-폴리시알산 항체 및 그 용도
CN120463807A (zh) 2018-03-22 2025-08-12 表面肿瘤学有限责任公司 抗il-27抗体及其用途
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
DK3775909T3 (da) 2018-03-26 2023-07-24 Glycanostics S R O Midler og fremgangsmåder til glykoprofilering af et protein
CN112313248A (zh) 2018-03-29 2021-02-02 百时美施贵宝公司 纯化单体单克隆抗体的方法
EP3774879B1 (de) 2018-03-30 2026-01-28 Amgen Inc. C-terminale antikörpervarianten
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
MX2020010094A (es) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス.アール.エル. Lgals3bp抗体−薬剤結合体及びがん治療のためのその使用
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CR20200459A (es) 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
CN112189018A (zh) 2018-04-20 2021-01-05 汉诺威医学院 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
TWI870348B (zh) 2018-04-30 2025-01-21 英商梅迪繆思有限公司 用於靶向及清除聚集體之結合物(conjugates)
AU2019262139A1 (en) 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. アレルゲンを含む改善されたlamp構築物
WO2019220368A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
EP3569614A1 (de) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
JP7549530B2 (ja) 2018-05-21 2024-09-11 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
EA202092849A1 (ru) 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
MX2020012598A (es) 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
BR112020023508A2 (pt) 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
GB201808617D0 (en) 2018-05-25 2018-07-11 Plant Bioscience Ltd Scaffold modification
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US12258395B2 (en) 2018-06-11 2025-03-25 University Of Florida Research Foundation, Incorporated Materials and methods for treating stress-related disorders and cancer
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
AU2019289176B2 (en) 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
CA3104295A1 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
JP7097465B2 (ja) 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するil-10剤の組成およびその使用方法
TW202017567A (zh) 2018-06-21 2020-05-16 美商優曼尼蒂治療股份有限公司 用於治療及預防神經病症之組成物及方法
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
EP3586865A1 (de) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020003077A1 (en) 2018-06-25 2020-01-02 Janssen Pharmaceutica Nv Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding
US12006357B2 (en) 2018-06-26 2024-06-11 Mor Research Applications Ltd. Transthyretin antibodies and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
KR102891320B1 (ko) 2018-07-11 2025-11-28 스칼러 락, 인크. 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
EP3820896A1 (de) 2018-07-11 2021-05-19 Scholar Rock, Inc. Tgfbeta1-inhibitoren und verwendung davon
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
ES3005559T3 (en) 2018-07-20 2025-03-14 Aicuris Anti Infective Cures Ag Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
EP3826625A4 (de) 2018-07-23 2022-08-24 Magenta Therapeutics, Inc. Verwendung von anti-cd5-antikörpermedikamentenkonjugat (adc) in der allogenen zelltherapie
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗-cd137抗体薬物コンジュゲート(adc)の使用
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
BR112021001683A2 (pt) 2018-08-01 2021-05-04 Cephalon, Inc. anticorpos anti-cxcr2 e usos dos mesmos
FI4177356T3 (fi) 2018-08-08 2024-08-07 Pml Screening Llc Menetelmiä virustaudin kehittymisriskin arviointiin geenitestillä
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033926A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
EP3837277A4 (de) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai Rekombinante viren der newcastle-krankheit und deren verwendungen zur prävention einer rsv-krankheit oder infektion mit dem menschlichen metapneumovirus
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
EP3847196A4 (de) 2018-09-07 2023-01-04 ITabMed (HK) Limited Bispezifische antigenbindende proteine und verwendungen davon
WO2020053122A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
EP3852617B1 (de) 2018-09-20 2025-09-10 SFJ Pharma X, Inc. Verwendung von antikörperfragmenten zur umkehrung der ticagrelor-aktivität
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス,インコーポレーテッド Csf1r/ccr2多特異性抗体
US20210380675A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
KR20210068079A (ko) 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
JP2022504287A (ja) 2018-10-03 2022-01-13 スターテン・バイオテクノロジー・ベー・フェー ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
IL281988B2 (en) 2018-10-05 2025-03-01 Bavarian Nordic As Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
EP3863722A2 (de) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap-antikörper und verwendungen davon
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
MA53920A (fr) 2018-10-17 2021-09-15 Janssen Biotech Inc Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
US20210380685A1 (en) 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
MX2021004598A (es) 2018-10-23 2021-06-15 Scholar Rock Inc Inhibidores selectivos de rgmc y el uso de los mismos.
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
US12129305B2 (en) 2018-10-25 2024-10-29 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L for treatment and prevention of cancer
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
EP3873912B1 (de) 2018-10-31 2026-03-25 Intocell, Inc. Kondensierte heterocyclische benzodiazepinderivate und verwendungen davon
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
CA3118027A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd. Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof
EP3877055A1 (de) 2018-11-05 2021-09-15 Ludwig Institute for Cancer Research Ltd Humanisierte und variante tgf-beta1-spezifische antikörper sowie verfahren und verwendungen davon
CN113015805B (zh) 2018-11-13 2024-12-03 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
JP7497351B2 (ja) 2018-11-13 2024-06-10 コンパス セラピューティクス リミテッド ライアビリティ カンパニー チェックポイント分子に対する多重特異性結合性構築物およびその使用
CA3119956A1 (en) 2018-11-14 2020-05-22 Daiichi Sankyo Company, Limited Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン,インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
CN113164594A (zh) 2018-11-20 2021-07-23 株式会社英仙蛋白质科学 向细胞内摄入铁的抑制剂
JP7625518B2 (ja) 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ 4-1bbl(cd137l)及び/またはcd40lをコードする組み換えmvaの腫瘍内及び/または静脈内投与によって、がんを治療する療法
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
AU2019399474B2 (en) 2018-12-13 2026-07-30 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
WO2020128927A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
CR20210326A (es) 2018-12-21 2021-09-10 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
US20220211798A1 (en) 2018-12-21 2022-07-07 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
US20200223925A1 (en) 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
US11447551B2 (en) 2018-12-28 2022-09-20 Sparx Bioscience Limited Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
MX2021004504A (es) 2019-01-02 2021-10-01 Neuracle Science Co Ltd Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
MA54752A (fr) 2019-01-14 2021-11-24 Univ Virginia Patent Foundation Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux
JP7539897B2 (ja) 2019-01-16 2024-08-26 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ヒトcd137に結合する抗体の製剤およびその使用
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
CA3127103A1 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
CN113383222A (zh) 2019-01-28 2021-09-10 贝克顿·迪金森公司 具有集成的拭子和测试装置的有害污染物收集装置
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
WO2020159445A1 (en) 2019-01-31 2020-08-06 Agency For Science, Technology And Research Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
EP3693063A1 (de) 2019-02-06 2020-08-12 Diaccurate Verfahren und zusammensetzungen zur behandlung von krebs
EP3696191A1 (de) 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car-t-zellen zur behandlung von cd1a-positivem krebs
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
WO2020169840A1 (en) 2019-02-21 2020-08-27 Cambridge Enterprise Limited Bispecific proteins with a chimeric scaffold
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
GB201902392D0 (en) 2019-02-21 2019-04-10 Cambridge Entpr Ltd Modular binding proteins
CN119735688A (zh) 2019-02-26 2025-04-01 茵思博纳公司 高-亲和力抗-mertk抗体及其用途
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
EP3932952A4 (de) 2019-02-28 2022-11-30 Juntendo Educational Foundation An trunkiertes mutantes calreticulin bindende antikörper und diagnostisches, prophylaktisches oder therapeutisches arzneimittel für myeloproliferative neoplasmen
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別tau之抗體
CA3133074A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
EP3938390A1 (de) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
JP7601758B2 (ja) 2019-03-19 2024-12-17 中外製薬株式会社 Mta依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
BR112021017616A2 (pt) 2019-03-25 2021-11-09 Daiichi Sankyo Co Ltd Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
AU2020247119A1 (en) 2019-03-25 2021-09-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Enhancement of cytolytic T-cell activity by inhibiting EBAG9
EP3950061A4 (de) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited Antikörper-pyrrolobenzodiazepinderivat-konjugat
EP3947446A1 (de) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Behandlung von tauopathie-erkrankungen durch abzielen auf neue tau-spezies
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
EP3949988A4 (de) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited Kombination aus einem antikörper-pyrrolobenzodiazepinderivat-konjugat und einem parp-hemmer
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
PH12021552414A1 (en) 2019-03-29 2022-07-25 Atarga Llc Anti fgf23 antibody
KR102829207B1 (ko) 2019-03-29 2025-07-02 브리스톨-마이어스 스큅 컴퍼니 크로마토그래피 수지의 소수성을 측정하는 방법
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
BR112021020204A2 (pt) 2019-04-10 2021-12-07 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo com região fc modificada
CN113677403B (zh) 2019-04-12 2024-12-27 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
CA3136892A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- psma/cd3 antibody
WO2020219719A1 (en) 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
EP3972690A4 (de) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha
CN114008073B (zh) 2019-05-23 2025-08-12 Ac免疫有限公司 抗tdp-43结合分子及其用途
WO2020243021A2 (en) 2019-05-24 2020-12-03 Foundation Medicine, Inc. Ntrk fusion molecules and uses thereof
JP2022534138A (ja) 2019-05-24 2022-07-27 インスティテュート・デ・メディチーナ・モレキュラ・ジョアオ・ロボ・アントゥネス Altがんの処置
IL288485B2 (en) 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
AU2020283890A1 (en) 2019-05-30 2021-12-16 Amgen Inc. Engineering the hinge region to drive antibody dimerization
US20200385453A1 (en) 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
US12594330B2 (en) 2019-06-04 2026-04-07 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN113905757B (zh) 2019-06-05 2026-01-13 中外制药株式会社 抗体切割位点结合分子
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
GB201908431D0 (en) 2019-06-12 2019-07-24 Plant Bioscience Ltd Biosynthetic genes and polypeptides
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
CA3143634A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
CN114630675A (zh) 2019-06-18 2022-06-14 爱尔兰詹森科学公司 乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ,インク. ポリペプチド
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
GB201909104D0 (en) * 2019-06-25 2019-08-07 Plant Bioscience Ltd Transferase enzymes
BR112021026293A2 (pt) 2019-06-26 2022-03-03 Hoffmann La Roche Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
EP3990492A1 (de) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Neuartige icos-antikörper und tumorspezifische antigenbindende moleküle damit
WO2020264384A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Pd−1/cd3二重特異性タンパク質による血液がん治療
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
US12655182B2 (en) 2019-07-15 2026-06-16 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof
BR112021005478A2 (pt) 2019-07-24 2021-06-15 H. Lundbeck A/S anticorpos anti-mglur5 e uso dos mesmos
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
EP4008350A4 (de) 2019-07-26 2023-06-14 Saitama Medical University Antikörper, der die extrazelluläre region von alk2/acvr1 erkennt
CA3149309A1 (en) 2019-07-30 2021-02-04 Ono Pharmaceutical Co., Ltd. Bispecific antibody
JP2022543553A (ja) 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Gprc5dに結合する抗体
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
WO2021018925A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
HUE064890T2 (hu) 2019-08-02 2024-04-28 Fundacio De Recerca Clinic Barcelona Inst BCMA elleni CAR T-sejtek mielóma multiplex kezelésére
EP4031658A1 (de) 2019-08-07 2022-07-27 DB Biotech, AS Verbesserte meerrettichperoxidase-polypeptide
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
KR20220042367A (ko) 2019-08-09 2022-04-05 에프. 호프만-라 로슈 아게 신규한 항-트로포닌t 항체
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
WO2021038078A1 (en) 2019-08-30 2021-03-04 4TEEN4 Pharmaceuticals GmbH Therapy guidance and/or therapy monitoring for treatment of shock
EP4021581A4 (de) 2019-08-30 2023-08-30 Foundation Medicine, Inc. Kmt2a-maml2-fusionsmoleküle und verwendungen davon
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
WO2021044009A1 (en) 2019-09-04 2021-03-11 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
US20230220098A1 (en) 2019-09-04 2023-07-13 Perseus Proteomics Inc. Therapeutic drug for polycythemia
EP4025606A1 (de) 2019-09-04 2022-07-13 Y-Biologics Inc. Anti-vsig4-antikörper oder antigenbindendes fragment und verwendungen davon
CN114929743B (zh) 2019-09-05 2026-01-02 纪念斯隆凯特琳癌症中心 抗steap1抗体及其用途
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與entpd2抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CA3151078A1 (en) 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
KR20220088428A (ko) 2019-09-26 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
US12441788B2 (en) 2019-09-27 2025-10-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-müllerian inhibiting substance antibodies and uses thereof
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
CN114746119A (zh) 2019-09-27 2022-07-12 詹森生物科技公司 抗-ceacam抗体及其用途
KR20220079590A (ko) 2019-10-04 2022-06-13 티에이이 라이프 사이언시스 Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
CN115003328A (zh) 2019-10-22 2022-09-02 西奈山伊坎医学院 重组神经氨酸酶及其用途
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
CN114630679A (zh) 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
JP7777524B2 (ja) 2019-11-04 2025-11-28 コード バイオセラピューティクス インコーポレイテッド 脳特異的血管新生抑制因子1(bai1)抗体及びその使用
CA3160482A1 (en) 2019-11-08 2021-05-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
EP4061405A1 (de) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Impfstoffe auf der basis von mutantem calr und jak2 und deren verwendungen
US20230047631A1 (en) 2019-11-19 2023-02-16 Amgen Inc. Novel multispecific antibody format
BR112022009798A2 (pt) 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
KR20220131895A (ko) 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
WO2021107082A1 (ja) 2019-11-27 2021-06-03 株式会社ペルセウスプロテオミクス 癌性腹膜炎の治療薬
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
CN115279789A (zh) 2019-12-06 2022-11-01 真和制药有限公司 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法
EP4072682A1 (de) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifität gegen her4 und verwendungen davon
AU2020408213A1 (en) 2019-12-19 2022-06-23 Ortho-Clinical Diagnostics, Inc. Monoclonal antibody fusions
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗-cd70抗體治療癌症之方法
EP4084821A4 (de) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. An cd33 bindende multifunktionsmoleküle und ihre verwendungen
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2021205877B2 (en) 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
CN115052663B (zh) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
IL294611B1 (en) 2020-01-08 2026-05-01 Regeneron Pharma Treatment of fibrodysplasia ossificans progressive
JP7675083B2 (ja) 2020-01-09 2025-05-12 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規4-1bbl三量体含有抗原結合分子
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN115315273A (zh) 2020-01-14 2022-11-08 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
EP4090335A1 (de) 2020-01-17 2022-11-23 Novartis AG Kombination aus einem tim-3-inhibitor und einem hypomethylierungsmittel zur verwendung bei der behandlung von myelodysplastischem syndrom oder chronischer myelomonozytischer leukämie
WO2021150925A1 (en) 2020-01-24 2021-07-29 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021154839A1 (en) 2020-01-30 2021-08-05 Umoja Biopharma, Inc. Bispecific transduction enhancer
KR20220137698A (ko) 2020-02-05 2022-10-12 라리마 테라퓨틱스, 인코포레이티드 Tat 펩티드 결합 단백질 및 이의 용도
BR112022015140A2 (pt) 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
TWI900527B (zh) 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
EP4103612A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9
US12673992B2 (en) 2020-02-13 2026-07-07 UCB Biopharma SRL Bispecific antibodies against CD9 and CD7
EP4103608A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd137
EP4103611B1 (de) 2020-02-13 2024-03-27 UCB Biopharma SRL Bispezifische, an hvem und cd9 bindende antikörper
WO2021160269A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
JP2023513834A (ja) 2020-02-18 2023-04-03 アレクトル エルエルシー Pilra抗体及びその使用方法
EP3871689A1 (de) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
CN115244401A (zh) 2020-02-27 2022-10-25 4Teen4制药有限公司 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3
CN115244081A (zh) 2020-02-27 2022-10-25 艾德里诺医药公司 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂
CA3168978A1 (en) 2020-02-27 2021-09-02 Andreas Bergmann Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
EP4114979A4 (de) 2020-03-04 2025-08-27 Found Medicine Inc Bcor-neuanordnungen und verwendungen davon
WO2021176424A1 (en) 2020-03-06 2021-09-10 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
JP7859981B2 (ja) 2020-03-06 2026-05-15 ジーオー セラピューティクス,インコーポレイテッド 抗グリコcd44抗体およびその使用
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
CA3174638A1 (en) 2020-03-11 2021-09-16 Fundacio Institut De Recerca Contra La Leucemia Josep Carreras Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
EP3922993A1 (de) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 bei patienten, die mit coronavirus infiziert sind
US20230213519A1 (en) 2020-03-16 2023-07-06 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CN115335082A (zh) 2020-03-27 2022-11-11 光爱科技公司 用于杀死肿瘤细胞的医药品
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
CA3175577A1 (en) 2020-03-30 2021-10-07 Mie University Bispecific antibody
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
EP4134099A4 (de) 2020-04-06 2024-05-29 PhotoQ3 Inc. Arzneimittel zur abtötung von tumorzellen
CA3173861A1 (en) 2020-04-10 2021-10-14 Rudolf Ubelhart Natural antibodies in prophylaxis and therapy
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
CA3168460A1 (en) 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2021263754A1 (en) 2020-04-27 2022-12-01 Ensoma, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
CA3181949A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4149512A4 (de) 2020-05-12 2024-06-05 Board of Regents, The University of Texas System Verfahren zur behandlung von glioblastom
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
PH12022553106A1 (en) 2020-05-17 2023-11-20 Astrazeneca Uk Liimited Sars-cov-2-antibodies and methods of selecting and using the same
TW202207977A (zh) 2020-05-19 2022-03-01 美商健生生物科技公司 包含t細胞重導向治療劑及vla-4黏附路徑抑制劑之組成物
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
ES2987329T3 (es) 2020-05-22 2024-11-14 Philogen Spa Terapia con el inmunoconjugado de TNF-a para el tratamiento de tumores cerebrales
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
PE20230389A1 (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
CN115803062B (zh) 2020-06-03 2025-09-09 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
CA3176552A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Immune activating fc domain binding molecules
TW202214704A (zh) 2020-06-19 2022-04-16 瑞士商赫孚孟拉羅股份公司 蛋白酶活化t細胞雙特異性抗體
CR20220627A (es) 2020-06-23 2023-02-17 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
EP4174071A4 (de) 2020-06-24 2024-09-11 The University of Tokyo Photosensibilisierender farbstoff
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
KR20230042273A (ko) 2020-06-24 2023-03-28 비스테라, 인크. April에 대한 항체 분자 및 그의 용도
CN115916830A (zh) 2020-06-25 2023-04-04 豪夫迈·罗氏有限公司 抗cd3/抗cd28双特异性抗原结合分子
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostata-neoantigene und ihre verwendungen
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
AU2021308574A1 (en) 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
CA3176556A1 (en) 2020-07-16 2022-01-20 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
US20230279078A1 (en) 2020-07-20 2023-09-07 Astrazeneca Uk Limited Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
TW202216744A (zh) 2020-07-20 2022-05-01 美商維埃拉生物股份有限公司 用於治療自體免疫性病症和炎性病症之免疫細胞介素
BR112023000216A2 (pt) 2020-07-28 2023-02-07 Chugai Pharmaceutical Co Ltd Preparação de seringa pré-carregada com agulha, com proteção de agulha e incluindo anticorpo modificado
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022024065A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
CN120040592A (zh) 2020-07-31 2025-05-27 百奥泰生物制药股份有限公司 Cd47抗体及其应用
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
JP2023534765A (ja) 2020-08-07 2023-08-10 フォーティス セラピューティクス,インク. 免疫複合体を標的とするcd46およびその使用方法
CN116615452A (zh) 2020-08-14 2023-08-18 Ac免疫有限公司 人源化抗tdp-43结合分子及其用途
AU2021328375A1 (en) 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
EP4200338A1 (de) 2020-08-20 2023-06-28 Amgen Inc. Antigenbindende proteine mit nichtkanonischem disulfid in der fab-region
US20240009310A1 (en) 2020-08-24 2024-01-11 Charité - Universitätsmedizin Berlin A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
AU2021334950A1 (en) 2020-08-24 2023-03-02 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
EP4204455A4 (de) 2020-08-25 2024-10-16 Janssen Biotech, Inc. Behandlung von nichtkleinzelligem lungenkrebs mit egfr-mutationen
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス,インコーポレーテッド Nkp30に結合する抗体分子およびその使用
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20230312689A1 (en) 2020-08-26 2023-10-05 National University Corporation Kumamoto University Human antibody or antigen-binding fragment thereof against coronavirus spike protein
EP4204448A2 (de) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2-antikörper zur makrophagen- und dendritischen zelldifferenzierung
WO2022045247A1 (ja) 2020-08-27 2022-03-03 学校法人順天堂 抗切断型変異calr-cd3二重特異性抗体及び医薬組成物
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4208197A1 (de) 2020-09-04 2023-07-12 Rutgers, The State University of New Jersey Sars-cov-2-impfstoffe und -antikörper
CN116829592A (zh) 2020-09-11 2023-09-29 免疫医疗有限公司 治疗性b7-h4结合分子
KR20230066095A (ko) 2020-09-12 2023-05-12 메디뮨 리미티드 항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법
US20230321087A1 (en) 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
AU2021346129A1 (en) 2020-09-16 2023-06-01 Janssen Biotech, Inc. Methods for treating multiple myeloma
EP4225786A2 (de) 2020-10-07 2023-08-16 Amgen Inc. Rationale auswahl von bausteinen zur anordnung multispezifischer antikörper
WO2022075439A1 (ja) 2020-10-08 2022-04-14 国立大学法人東海国立大学機構 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
EP4228764A1 (de) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-chemokinrezeptor-8-(ccr8)-antikörper und verfahren zur verwendung davon
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
CA3198049A1 (en) 2020-10-15 2022-04-21 UCB Biopharma SRL Binding molecules that multimerise cd45
EP4232475A1 (de) 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antikörper oder antigenbindende fragmente mit spezifischer bindung an gremlin-1 und verwendungen davon
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
MX2023004724A (es) 2020-10-23 2024-02-23 Hq Han Antagonistas bifuncionales de la activina y del factor alfa de necrosis tumoral y usos de los mismos.
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
EP4244246A1 (de) 2020-11-10 2023-09-20 Amgen Inc. Neue linker von multispezifischen antigenbindenden domänen
EP4253415A4 (de) 2020-11-12 2024-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Antikörper und herstellungsverfahren dafür
US12704517B2 (en) 2020-11-24 2026-08-11 Bio-Techne Corporation Anti-severe acute respiratory syndrome coronavirus antibodies
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
AU2021390501A1 (en) 2020-12-01 2023-06-29 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4023218A1 (de) 2020-12-02 2022-07-06 S-Form Pharma Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
KR20230117122A (ko) 2020-12-04 2023-08-07 에프. 호프만-라 로슈 아게 pH 의존성 돌연변이체 인터류킨-2 폴리펩티드
EP4259661A1 (de) 2020-12-14 2023-10-18 Novartis AG Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
WO2022130023A1 (en) 2020-12-14 2022-06-23 University Health Network Immunoglobulin light chain antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
MX2023007028A (es) 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4277665A1 (de) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3-antikörper-wirkstoff-konjugat
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
WO2022159590A1 (en) 2021-01-20 2022-07-28 Visterra, Inc. Interleukin-2 mutants and uses thereof
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
MX2023008909A (es) 2021-01-28 2023-10-23 Janssen Biotech Inc Proteínas de unión a psma y usos de estas.
EP4284510A1 (de) 2021-01-29 2023-12-06 Novartis AG Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
US20240230671A9 (en) 2021-02-24 2024-07-11 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
WO2022187440A1 (en) 2021-03-03 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services La protien as a novel regulator of osteoclastogenesis
EP4301782A1 (de) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44-antikörper und deren verwendungen
AU2022231874A1 (en) 2021-03-09 2023-07-27 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
IL305700A (en) 2021-03-09 2023-11-01 Janssen Biotech Inc Treatment of cancers lacking EFGR-activating mutations
CN117015555A (zh) 2021-03-09 2023-11-07 豪夫迈·罗氏有限公司 Pd-1靶向il-2变体免疫缀合物和抗tyrp1/抗cd3双特异性抗体的组合疗法
EP4305062A1 (de) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Verfahren zur behandlung von patienten mit psoriasisarthritis mit unzureichender reaktion auf eine tnf-therapie mit anti-il23-spezifischem antikörper
CN117320749A (zh) 2021-03-12 2023-12-29 中外制药株式会社 用于治疗或预防重症肌无力的药物组合物
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
EP4308603A1 (de) 2021-03-17 2024-01-24 Receptos Llc Verfahren zur behandlung von atopischer dermatitis mit anti-il-13-antikörpern
EP4308607A2 (de) 2021-03-18 2024-01-24 MedImmune Limited An ccr9 bindendes therapeutisches bindungsmolekül
EP4308935A1 (de) 2021-03-18 2024-01-24 Novartis AG Biomarker für krebs und verfahren zur verwendung davon
JP7797523B2 (ja) 2021-03-24 2026-01-13 ワッカー ケミー アクチエンゲゼルシャフト 不飽和基を有するオルガノポリシロキサンの製造方法
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304991A (zh) 2021-03-29 2023-02-01 日商第一三共股份有限公司 穩定的多重特異性分子及其利用
WO2022207521A1 (en) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Protease-activated polypeptides
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
EP4323399A4 (de) 2021-04-14 2025-04-09 Kodiak Sciences Inc. Verfahren zur behandlung einer augenerkrankung
US20240182600A1 (en) 2021-04-20 2024-06-06 Amgen Inc. Balanced Charge Distribution in Electrostatic Steering of Chain Pairing in Multi-specific and Monovalent IgG Molecule Assembly
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
US12472248B2 (en) 2021-04-29 2025-11-18 The Government Of The United States, As Represented By The Secretary Of The Army Antibodies against fentanyl and fentanyl analogs
BR112023022878A2 (pt) 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
AU2022270170A1 (en) 2021-05-07 2023-09-21 Surface Oncology, LLC Anti-il-27 antibodies and uses thereof
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及/或難治性多發性骨髓瘤之治療的方法及組成物
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
TW202309094A (zh) 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
JP2024518200A (ja) 2021-05-18 2024-04-30 ヤンセン バイオテツク,インコーポレーテツド T細胞リダイレクト治療薬及び抗cd44治療薬を含む組成物
AU2022281461A1 (en) 2021-05-25 2024-01-04 Edelweiss Immune Inc C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4348260A2 (de) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitoren und deren therapeutische verwendung
US20240277842A1 (en) 2021-06-07 2024-08-22 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
KR20240021943A (ko) 2021-06-18 2024-02-19 남미 테라퓨틱스, 인크. 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법
DK4358995T3 (da) 2021-06-23 2026-02-02 Scholar Rock Inc Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser
US20240165229A1 (en) 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
IL309345A (en) 2021-07-01 2024-02-01 Albert Einstein College Medicine Compositions and methods for inhibiting the expression of tmigd2
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング,インコーポレイテッド タンパク質凝集を防止する方法
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
EP4370541A1 (de) 2021-07-14 2024-05-22 2seventy bio, Inc. Gentechnisch hergestellte t-zell-rezeptoren, die an bindungsdomänen aus antikörpern fusioniert sind
JPWO2023286854A1 (de) 2021-07-16 2023-01-19
CA3226281A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
US20250270314A1 (en) 2021-08-02 2025-08-28 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
US20250277051A1 (en) 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス,インコーポレイテッド 抗グリコmuc抗体およびその使用
IL310535A (en) 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
AU2022335718A1 (en) 2021-08-26 2024-03-28 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
KR20240049363A (ko) 2021-08-26 2024-04-16 가부시키가이샤 페르세우스 프로테오믹스 Ros(활성 산소종) 생산 증강제
WO2023032955A1 (ja) 2021-08-31 2023-03-09 大正製薬株式会社 抗成長ホルモン抗体
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (ja) 2021-09-03 2024-09-26 ジーオー セラピューティクス,インコーポレイテッド 抗グリコlamp1抗体およびその使用
JP2024534918A (ja) 2021-09-03 2024-09-26 ユニバーシティ オブ ベルン Qt延長症候群を治療するための組成物及び方法
EP4144898A1 (de) 2021-09-07 2023-03-08 New/era/mabs GmbH Verfahren zur selektion oder screenen von antikörpern aus einer antikörperbibliothek
JP2024531711A (ja) 2021-09-14 2024-08-29 グリカノスティクス エス.アール.オー. 乳がんにおけるマンマグロビンaグリコフォームを測定するためのレクチンの使用法
US20240390512A1 (en) 2021-09-15 2024-11-28 Daiichi Sankyo Company, Limited Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
JP2024535888A (ja) 2021-09-20 2024-10-02 アルナイラム ファーマシューティカルズ, インコーポレイテッド インヒビンサブユニットベータe(inhbe)モジュレーター組成物およびその使用方法
US20250000998A1 (en) 2021-09-24 2025-01-02 PhotoQ3 Inc. Medicament for killing tumor cells
US20250084155A1 (en) 2021-09-29 2025-03-13 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
EP4412583B1 (de) 2021-10-04 2026-07-08 Novartis AG Tensidstabilisatoren
EP4413998A4 (de) 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung einer vorgefüllten spritzenformulierung
PE20241627A1 (es) 2021-10-14 2024-08-07 Hoffmann La Roche Nuevos inmunoconjugados de interleucina-7
EP4429706A1 (de) 2021-10-14 2024-09-18 F. Hoffmann-La Roche AG Alternative pd1-il7v-immunkonjugate zur behandlung von krebs
EP4420683A1 (de) 2021-10-18 2024-08-28 Daiichi Sankyo Company, Limited Anti-cd37-antikörper-wirkstoff-konjugat
CN118355030A (zh) 2021-10-18 2024-07-16 拓维创新生物科技(香港)有限公司 抗EGFR抗体、抗cMET抗体、抗VEGF抗体、多特异性抗体及其用途
CA3235627A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4426437A4 (de) 2021-11-03 2025-09-17 Janssen Biotech Inc Verfahren zur behandlung von krebs und erhöhung der wirksamkeit von bispezifischen bcmaxcd3-antikörpern
EP4177266A1 (de) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralisierende humane anti-sars-cov-2-antikörper
EP4433167A1 (de) 2021-11-16 2024-09-25 AC Immune SA Moleküle für therapie und diagnose
JP7748680B2 (ja) 2021-11-16 2025-10-03 国立大学法人鳥取大学 改変d領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202440647A (zh) 2021-11-19 2024-10-16 英商米羅比奧有限公司 經工程改造之pd-1抗體及其用途
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
CN118284625A (zh) 2021-11-26 2024-07-02 豪夫迈·罗氏有限公司 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023100829A1 (ja) 2021-11-30 2023-06-08 第一三共株式会社 プロテアーゼ分解性マスク抗体
KR20240011866A (ko) 2021-12-01 2024-01-26 추가이 세이야쿠 가부시키가이샤 항체 함유 제제의 조제 방법
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
WO2023107957A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
WO2023104154A1 (zh) 2021-12-08 2023-06-15 安达生物药物开发(深圳)有限公司 抗原性多肽及其用途
US20230183360A1 (en) 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
JP2025503439A (ja) 2021-12-17 2025-02-04 アボット・ラボラトリーズ 血液試料におけるuch-l1、gfap及び他のバイオマーカーを決定するためのシステム及び方法
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CA3248133A1 (en) 2022-01-24 2023-07-27 Novimmune Sa COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
EP4472733A1 (de) 2022-01-31 2024-12-11 BYOMass Inc. Myeloproliferative erkrankungen
JP2025507303A (ja) 2022-02-04 2025-03-18 アボット・ラボラトリーズ 試料におけるユビキチンカルボキシ末端ヒドロラーゼl1及び/又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
JP2025506122A (ja) 2022-02-10 2025-03-07 アムジエン・インコーポレーテツド ハイスループット配列決定のための抗体タンパク質産物発現コンストラクト
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
AU2023226293A1 (en) 2022-02-25 2024-09-05 Juntendo Educational Foundation Medicine comprising combination of anti-mutant-calr antibody and another drug
EP4486769A1 (de) 2022-03-02 2025-01-08 Heidelberg ImmunoTherapeutics GmbH Impfstoff mit einem antikörper oder einem fc-haltigen fusionsprotein mit einem fc-teil eines antikörpers
EP4490192A1 (de) 2022-03-07 2025-01-15 Novimmune S.A. Cd28-bispezifische antikörper zur gezielten t-zell-aktivierung
EP4490187A4 (de) 2022-03-08 2026-02-25 Immunedge Inc Epo-rezeptor-agonisten und -antagonisten
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
EP4490517A1 (de) 2022-03-11 2025-01-15 Astrazeneca AB Bewertungsverfahren für eine anti-fr-alpha-antikörper-wirkstoff-konjugattherapie
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
CN119072492A (zh) 2022-03-15 2024-12-03 艾德里诺医药公司 抗肾上腺髓质素(adm)抗体或抗adm抗体片段的稳定水性制剂
WO2023176881A1 (ja) 2022-03-16 2023-09-21 第一三共株式会社 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
AR128876A1 (es) 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
WO2023196866A1 (en) 2022-04-06 2023-10-12 Mirobio Limited Engineered cd200r antibodies and uses thereof
WO2023195532A1 (ja) 2022-04-07 2023-10-12 ブライトパス・バイオ株式会社 ヒトtim-3およびヒトcd39に対する二重特異性抗体およびその用途
WO2023194539A1 (en) 2022-04-07 2023-10-12 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index of amatoxin-antibody conjugates
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
IL316153A (en) 2022-04-08 2024-12-01 Ac Immune Sa Anti-tdp-43 binding molecules
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use
US20250263497A1 (en) 2022-04-19 2025-08-21 Tokai University Educational System Therapeutic agent for nk-cell tumor
AU2023258146A1 (en) 2022-04-20 2024-09-05 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
AU2023262513A1 (en) 2022-04-25 2024-12-05 Visterra, Inc. Antibody molecules to april and uses thereof
KR20250005335A (ko) 2022-04-26 2025-01-09 추가이 세이야쿠 가부시키가이샤 의약 제제 함유 필터 내장 시린지
IL316174A (en) 2022-04-26 2024-12-01 Novartis Ag Multiple specific antibodies targeting IL-13 and IL-18
CR20240528A (es) 2022-04-29 2025-04-04 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y métodos para utilizarlos
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN119255825A (zh) 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
GB202209501D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Biosynthetic enzymes
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
CN119790073A (zh) 2022-06-30 2025-04-08 詹森生物科技公司 使用抗EGFR/抗Met抗体治疗胃癌或食道癌
AU2023298151A1 (en) 2022-07-01 2025-01-02 Neurogene Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
US20250382657A1 (en) 2022-07-07 2025-12-18 Cambridge Enterprise Limited Methods for mapping binding sites of compounds
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
US20260028423A1 (en) 2022-07-29 2026-01-29 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
IL318667A (en) 2022-07-29 2025-03-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
CA3263767A1 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
WO2024043227A1 (ja) 2022-08-23 2024-02-29 小野薬品工業株式会社 二重特異性抗体
UY40407A (es) 2022-08-31 2024-03-15 Washington University St Louis Moléculas de unión al antígeno alfavirus y usos de las mismas
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024050526A1 (en) 2022-09-02 2024-03-07 Biomarin Pharmaceutical Inc. Compositions and methods for treating long qt syndrome
CA3266977A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
EP4584291A1 (de) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antikörper mit spezifität gegen ltbp2 und verwendungen davon
JPWO2024053719A1 (de) 2022-09-08 2024-03-14
EP4585226A1 (de) 2022-09-09 2025-07-16 Institute Of Science Tokyo Therapeutikum für coronavirus-infektion
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
CA3262904A1 (en) 2022-09-21 2024-03-28 Elthera Ag NEW BINDING MOLECULES THAT BIND TO L1CAM
EP4594353A1 (de) 2022-09-28 2025-08-06 F. Hoffmann-La Roche AG Verbesserte protease-aktivierbare bispezifische t-zell-antikörper
CN119948048A (zh) 2022-09-29 2025-05-06 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
EP4345109A1 (de) 2022-09-30 2024-04-03 AdrenoMed AG Anti-adrenomedullin (adm)-bindemittel zur verwendung bei der behandlung von pädiatrischen patienten mit angeborener herzerkrankung
CN120882864A (zh) 2022-09-30 2025-10-31 国立大学法人 东京大学 靶向il13ra2的单纯疱疹病毒及抗il13ra2抗体或其抗原结合片段
IL320230A (en) 2022-10-14 2025-06-01 Janssen Pharmaceutica Nv A method for detecting antibody-dependent cellular phagocytosis
WO2024084463A1 (en) 2022-10-21 2024-04-25 Janssen Research & Development, Llc Methods and systems for microbial detection using infrared spectroscopy
CN120380325A (zh) 2022-10-21 2025-07-25 詹森药业有限公司 使用拉曼光谱进行微生物检测的方法和系统
CN120418442A (zh) 2022-10-21 2025-08-01 詹森药业有限公司 用于微生物检测的方法
AU2023362569A1 (en) 2022-10-21 2025-04-24 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
TW202426486A (zh) 2022-10-25 2024-07-01 日商第一三共股份有限公司 使用針對抑制型kir的促效劑的免疫排斥之迴避方法
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
IL320562A (en) 2022-11-02 2025-07-01 Janssen Biotech Inc Cancer treatment methods
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
US20260191905A1 (en) 2022-12-01 2026-07-09 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
US20260201067A1 (en) 2022-12-15 2026-07-16 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
US20260217861A1 (en) 2022-12-22 2026-07-30 Jjulius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
EP4649149A1 (de) 2023-01-10 2025-11-19 Fundação GIMM - Gulbenkian Institute for Molecular Medicine Induktion von zellulärer letalität bei krebs
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
WO2024153722A1 (en) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Immunoconjugates
CN120548364A (zh) 2023-01-27 2025-08-26 第一三共株式会社 抗lrrc15抗体
US20260217828A1 (en) 2023-01-31 2026-07-30 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
TW202448960A (zh) 2023-02-07 2024-12-16 美商Go治療公司 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
WO2024169990A1 (zh) 2023-02-13 2024-08-22 浙江大学绍兴研究院 双特异性抗体及其应用
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
TW202448927A (zh) 2023-02-28 2024-12-16 美商健生生物科技公司 包含雙特異性gprc5d/cd3抗體之組成物
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
AU2024236678A1 (en) 2023-03-13 2025-10-30 Janssen Biotech, Inc. Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
EP4431526A1 (de) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi-antikörper und funktionelle fragmente davon
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
EP4680966A1 (de) 2023-03-17 2026-01-21 PAM Theragnostics GmbH Verfahren zur bestimmung der peptidylglycin-alpha-amidierenden monooxygenase (pam) und deren verwendung für diagnostische zwecke
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
JP2026513177A (ja) 2023-03-29 2026-04-23 4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのdpp3阻害剤
KR20250164708A (ko) 2023-03-29 2025-11-25 다이이찌 산쿄 가부시키가이샤 항 cd25 항체 및 항 cd25 항체-약물 콘주게이트
JP2026517628A (ja) 2023-04-04 2026-06-02 アボット・ラボラトリーズ 対象が亜急性後天性脳損傷(abi)を負った、負った可能性がある、又は負っていると推測されるかどうかを決定するためのバイオマーカーの使用
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法
JPWO2024219442A1 (de) 2023-04-19 2024-10-24
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
AU2024265613A1 (en) 2023-05-04 2025-09-25 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
CN121358776A (zh) 2023-05-09 2026-01-16 詹森生物科技公司 包含高浓度的双特异性bcma/cd3抗体的药物组合物
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
EP4720121A1 (de) 2023-06-01 2026-04-08 F. Hoffmann-La Roche AG Immunstimulierende antigenbindende moleküle, die spezifisch an bcma binden
TW202504918A (zh) 2023-06-01 2025-02-01 瑞士商赫孚孟拉羅股份公司 靶向bcma及cd28的雙特異性抗體
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
AU2024304180A1 (en) 2023-06-13 2026-01-08 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
JP2026520211A (ja) 2023-06-16 2026-06-22 ハイデルべルク イミュノセラピューティクス ゲーエムベーハー 新規の抗hsv抗体
CN119143869A (zh) 2023-06-16 2024-12-17 复旦大学 乙肝病毒表面抗体及其应用
CN121729432A (zh) 2023-06-23 2026-03-24 派克西斯肿瘤学公司 抗klrg1抗体及其用途
EP4484445A1 (de) 2023-06-26 2025-01-01 Universität zu Köln Hcmv neutralisierende antikörper
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
EP4743494A1 (de) 2023-07-14 2026-05-20 Janssen Biotech, Inc. Dosierschema für therapien mit bispezifischen antiegfr/c-met-antikörpern
KR20260048598A (ko) 2023-07-31 2026-04-10 아스트라제네카 아베 Cd123 항체-약물 접합체 및 이의 사용 방법
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
CN117247454A (zh) 2023-08-22 2023-12-19 华中科技大学同济医学院附属协和医院 靶向gpc3的分子探针以及用途
WO2025049272A1 (en) 2023-08-25 2025-03-06 The Broad Institute, Inc. Card9 variant polypeptide and antibodies directed thereto
IL326946A (en) 2023-09-05 2026-05-01 Janssen Biotech Inc Methods of treating non-small cell lung cancer
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases
WO2025051895A1 (en) 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
AU2024339935A1 (en) 2023-09-14 2026-04-09 Medizinische Universität Innsbruck Enhancement of car-t cell efficacy by inhibiting nr2f6
EP4527851A1 (de) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispezifische antikörperzur bindung von ltbr und lrrc15
CN121889677A (zh) 2023-09-25 2026-04-17 思芬构技术有限公司 用于肾移植患者中移植物功能降低的早期诊断、早期预测、监测或严重程度预测的方法
CN121941710A (zh) 2023-09-27 2026-04-28 艾尔瑟拉股份有限公司 用于治疗血液恶性肿瘤疾病的l1cam结合分子
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
AU2024370419A1 (en) 2023-10-31 2026-06-11 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma
WO2025094107A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
IL328139A (en) 2023-11-01 2026-06-01 Janssen Biotech Inc Methods for treating multiple myeloma
JPWO2025105486A1 (de) 2023-11-17 2025-05-22
WO2025114411A1 (en) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale New method to treat brain or neurologic disorders
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN122349567A (zh) 2023-12-11 2026-07-07 济世易为生物有限公司 利用反式剪接和拆分型选择标记的蛋白质表达
EP4570262A1 (de) 2023-12-15 2025-06-18 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Chimärer antigenrezeptor gegen den chemokinrezeptor ccr7
IL328822A (en) 2023-12-19 2026-08-01 Cephalon Llc Uses for attenuated IL-2 immunosuppressants
AU2024403128A1 (en) 2023-12-19 2026-06-25 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
AU2025206074A1 (en) 2024-01-03 2026-07-02 Kiniksa Pharmaceuticals, Gmbh Method of reducing aggregation in the virus-inactivated preparation of anti-cd40 antibodies
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
TW202547867A (zh) 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025160261A2 (en) 2024-01-23 2025-07-31 Cephalon Llc Chemical dehydration and suspension delivery of protein drug products
TW202540204A (zh) 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法
GB202401567D0 (en) 2024-02-06 2024-03-20 St Georges Hospital Medical School Treatment of infectious disease
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
WO2025202147A1 (en) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Interleukin-7 immunoconjugates
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025226390A1 (en) 2024-04-23 2025-10-30 Cephalon Llc Use of rapamycin for improved antibody production
WO2025224679A1 (en) 2024-04-24 2025-10-30 Janssen Pharmaceutica Nv Methods and systems for microbial detection using raman and infrared spectroscopy
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025229538A1 (en) 2024-05-01 2025-11-06 Janssen Biotech, Inc. Materials, methods, and systems for cellular expansion of gamma delta t-cells
WO2025229075A1 (en) 2024-05-03 2025-11-06 Sphingotec Gmbh A method for the specific determination of proenkephalin fragment 119-159
US20260041768A1 (en) 2024-05-03 2026-02-12 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025235420A1 (en) 2024-05-06 2025-11-13 Generate Biomedicines, Inc. Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025235419A1 (en) 2024-05-06 2025-11-13 Generate Biomedicines, Inc. Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025233304A1 (en) 2024-05-08 2025-11-13 F. Hoffmann-La Roche Ag Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
EP4650368A1 (de) 2024-05-13 2025-11-19 Epok Therapeutics Inc. Tetravalente erythropoietinrezeptoragonisten
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
EP4653460A1 (de) 2024-05-23 2025-11-26 Egle Therapeutics Il18r-agonist-antikörper und verwendungen davon
WO2025243241A1 (en) 2024-05-23 2025-11-27 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025242910A1 (en) 2024-05-23 2025-11-27 Egle Therapeutics Il18r agonist antibodies and uses thereof
TW202615468A (zh) 2024-05-29 2026-04-16 美商健生生物科技公司 局部晚期或轉移性egfr突變之非小細胞肺癌之治療
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same
EP4674430A1 (de) 2024-07-01 2026-01-07 Universität zu Köln Editierte zytotoxische zellen mit chimären antigenrezeptoren zum targeting von cd30 zur behandlung von infektionen
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
EP4675277A1 (de) 2024-07-05 2026-01-07 Predemtec AG Verfahren zur diagnose von morbus alzheimer oder zur bestimmung des risikos des leidens an morbus alzheimer
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof
WO2026017820A1 (en) 2024-07-18 2026-01-22 Egle Therapeutics Fusion protein for cancer treatment
EP4681780A1 (de) 2024-07-18 2026-01-21 Egle Therapeutics Immunozytokine zur krebsbehandlung
WO2026022721A1 (en) 2024-07-26 2026-01-29 Janssen Biotech, Inc. Anti-tnfr2 antibodies
WO2026028163A1 (en) 2024-08-01 2026-02-05 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies
WO2026033437A1 (en) 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026036047A1 (en) 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
WO2026037841A1 (en) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Anti-fgfr4 molecules and uses thereof
CA3278557A1 (en) 2024-08-13 2026-03-01 Janssen Biotech, Inc. Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies
WO2026038160A1 (en) 2024-08-13 2026-02-19 Janssen Biotech, Inc. Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)
WO2026046947A1 (en) 2024-08-26 2026-03-05 4TEEN4 Pharmaceuticals GmbH Anti-dpp3 antibody directed to and binding to dpp3 for the treatment of shock in extreme-critically ill patients
WO2026046978A1 (en) 2024-08-26 2026-03-05 Pam Theragnostics Gmbh Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects
WO2026046982A1 (en) 2024-08-26 2026-03-05 Pam Theragnostics Gmbh A method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (iect)
WO2026046968A1 (en) 2024-08-26 2026-03-05 4TEEN4 Pharmaceuticals GmbH Dpp3 binders for the treatment of endothelial dysfunction
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026052582A1 (en) 2024-09-04 2026-03-12 Red Ridge Bio Ag Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3
WO2026055167A1 (en) 2024-09-05 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and use of biomarkers in uses thereof
WO2026055461A1 (en) 2024-09-05 2026-03-12 Aperture Therapeutics, Inc. Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
WO2026055168A1 (en) 2024-09-06 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and uses and doses thereof
US20260167709A1 (en) 2024-09-11 2026-06-18 Novartis Ag Antibodies targeting il-31
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
WO2026057740A1 (en) 2024-09-12 2026-03-19 Astrazeneca Ab Treatment of cancer with therapeutic binding molecules
US20260083857A1 (en) 2024-09-23 2026-03-26 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof
WO2026088159A1 (en) 2024-10-24 2026-04-30 Imuno Therapeutics Hla-a2 p53 antibodies and methods of use thereof
WO2026090579A1 (en) 2024-10-25 2026-04-30 Janssen Biotech, Inc. Methods of treating smoldering multiple myeloma with ciltacabtagene autoleucel
WO2026096383A1 (en) 2024-10-28 2026-05-07 The Broad Institute, Inc. Compositions and methods for inducing phagocytosis
US20260116978A1 (en) 2024-10-28 2026-04-30 Tae Life Sciences Llc Methods of Performing Boron Neutron Capture Therapy (BNCT) in Combination with Immune Checkpoint Inhibitors to Enhance BNCT and the Anti-tumor effects of Immune Check Point Inhibitors as well as the Abscopal Effect Induced by Radiation Therapy and Methods Thereof
WO2026095974A1 (en) 2024-10-30 2026-05-07 Horizon Therapeutics Ireland Dac Methods of treating thyroid eye disease
WO2026093993A1 (en) 2024-11-01 2026-05-07 Janssen Biotech, Inc. Methods and systems for enhanced multispecific metabolic and cellular targeting
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026104323A1 (en) 2024-11-12 2026-05-21 F. Hoffmann-La Roche Ag Targeted flt3l immunoconjugates and methods of use
WO2026104336A1 (en) 2024-11-13 2026-05-21 F. Hoffmann-La Roche Ag Immunoconjugates
WO2026112563A1 (en) 2024-11-25 2026-05-28 Abbott Laboratories Systems and methods for tbi adjudication
WO2026117686A1 (en) 2024-11-27 2026-06-04 Nammi Therapeutics, Inc. FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
WO2026117756A2 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Systems and methods for expression of synthetic cancer antigens and cytokine receptors
WO2026136288A2 (en) 2024-12-18 2026-06-25 Generate Biomedicines, Inc. Antibodies or antigen-binding fragments thereof capable of binding to free drug and uses thereof
WO2026132786A1 (en) 2024-12-20 2026-06-25 Centessa Pharmaceuticals (Uk) Limited Anti-cd3 binding agents and uses thereof
WO2026147818A1 (en) 2024-12-30 2026-07-09 Als Therapy Development Institute Antibodies that bind to post-translationally modified c9orf72 arginine-rich dipeptide repeat proteins and uses thereof
WO2026147633A1 (en) 2025-01-02 2026-07-09 The Board Of Regents Of The University Of Oklahoma Hemicyanine compounds having optoacoustic properties and methods of use
WO2026148288A1 (en) 2025-01-06 2026-07-09 M2 Therapeutics, Inc. Antibodies and antigen-binding fragments thereof to growth hormone receptor and methods of use
WO2026151679A1 (en) 2025-01-07 2026-07-16 Compass Therapeutics, Llc. Multispecific binding constructs targeting pd-1 and vegf and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1277931C (en) 1984-06-05 1990-12-18 Shimon Ulitzur Detection and/or identification of microorganisms in a test sample usingbioluminescence or other exogenous genetically-introduced marker
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
EP0281604B1 (de) 1986-09-02 1993-03-31 Enzon Labs Inc. Bindungsmoleküle mit einzelpolypeptidkette
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1988006630A1 (en) * 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
JPH02500329A (ja) * 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3744595A1 (de) * 1987-12-31 1989-07-13 Andreas Dr Plueckthun Verfahren zur gentechnischen herstellung von antikoerpern
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5688666A (en) 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
SE8901203D0 (sv) 1989-04-06 1989-04-06 Bofors Ab Ammunition
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
EP0478627A4 (en) * 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) * 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
WO1991012328A1 (en) 1990-02-15 1991-08-22 Fowlkes Dana M Totally synthetic affinity reagents
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
IE914504A1 (en) 1990-12-20 1992-07-01 Ixsys Optimization of binding proteins
PT100379B (pt) * 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) * 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
GB9120252D0 (en) 1991-09-23 1991-11-06 Cambridge Antibody Tech Improvement binding substances
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9125582D0 (en) 1991-12-02 1992-01-29 Cambridge Antibody Tech Binding molecules 2
WO1994005781A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Phagemids coexpressing a surface receptor and a surface heterologous protein
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5561610A (en) * 1994-06-30 1996-10-01 Caterpillar Inc. Method and apparatus for indicating a fault condition
DE20114623U1 (de) 2001-09-04 2004-02-12 Wilken, Wilhelm, Dr. Distaler Adapter für T5 Leuchtstofflampen mit Nachrüst-EVG
US8464209B2 (en) 2007-03-19 2013-06-11 Microsoft Corporation Using collaborative development information in a team environment

Also Published As

Publication number Publication date
ATE447023T1 (de) 2009-11-15
LU91623I2 (en) 2010-01-11
DE69123156T2 (de) 1997-04-17
US20100317540A1 (en) 2010-12-16
DE69123156T3 (de) 2006-11-30
ES2285292T3 (es) 2007-11-16
KR100222326B1 (en) 1999-10-01
US5969108A (en) 1999-10-19
EP2055777A3 (de) 2009-05-13
EP0844306A1 (de) 1998-05-27
EP2055777B1 (de) 2009-10-28
DE122010000026I2 (de) 2011-06-09
US7723270B1 (en) 2010-05-25
ATE212663T1 (de) 2002-02-15
ES2096655T5 (es) 2006-04-16
ES2322323T3 (es) 2010-04-08
JPH05508076A (ja) 1993-11-18
DE69133568D1 (de) 2007-05-16
DK0774511T3 (da) 2002-05-13
EP1754787B1 (de) 2012-01-25
DK1433846T3 (da) 2007-08-20
GB9022845D0 (en) 1990-12-05
DE69133545T2 (de) 2007-05-24
DE69133545D1 (de) 2006-10-26
EP1847605A2 (de) 2007-10-24
EP1433846B1 (de) 2007-04-04
AU664155B2 (en) 1995-11-09
GR3022126T3 (en) 1997-03-31
DK0844306T3 (da) 2007-01-29
EP0844306B1 (de) 2006-09-13
EP1847605A3 (de) 2007-10-31
ATE358720T1 (de) 2007-04-15
EP0774511A1 (de) 1997-05-21
EP2055777A2 (de) 2009-05-06
DK2055777T3 (da) 2010-03-01
US20090155810A1 (en) 2009-06-18
US20070148774A1 (en) 2007-06-28
DK0589877T4 (da) 2006-03-06
WO1992001047A1 (en) 1992-01-23
DE69132920T2 (de) 2002-11-21
ATE145237T1 (de) 1996-11-15
EP0589877B1 (de) 1996-11-13
NL300423I1 (nl) 2010-01-04
DE69132920D1 (de) 2002-03-14
EP1754787A3 (de) 2008-06-18
US7635666B1 (en) 2009-12-22
DE122010000026I1 (de) 2010-08-12
EP0589877A1 (de) 1994-04-06
JP3176917B2 (ja) 2001-06-18
EP1433846A3 (de) 2004-09-22
CA2086936A1 (en) 1992-01-11
ES2275280T3 (es) 2007-06-01
ES2096655T3 (es) 1997-03-16
HK1131637A1 (en) 2010-01-29
EP0589877B2 (de) 2005-10-26
US20120129710A1 (en) 2012-05-24
EP0774511B1 (de) 2002-01-30
DE69123156D1 (de) 1996-12-19
ES2171581T3 (es) 2002-09-16
DE69133568T2 (de) 2008-01-03
DE69132920C5 (de) 2013-05-16
EP1433846A2 (de) 2004-06-30
DK0589877T3 (da) 1997-04-07
EP1754787A2 (de) 2007-02-21
ATE339497T1 (de) 2006-10-15
CA2086936C (en) 2005-08-16
GB9015198D0 (en) 1990-08-29
DE69133625D1 (de) 2009-12-10
DE09001901T1 (de) 2009-09-03
ES2322323T1 (es) 2009-06-19
AU8221691A (en) 1992-02-04

Similar Documents

Publication Publication Date Title
ATE447023T1 (de) Verfahren zur herstellung von spezifischen bindungspaargliedern
ATE185601T1 (de) Verfahren zur herstellung von spezifischen bindungspaargliedern
ATE296879T1 (de) Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
ATE313633T1 (de) Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren
EP1027437B8 (de) Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
WO2002059309A3 (en) Anthozoa derived chromoproteins, fluorescent mutants thereof and methods for using the same
DK0870050T3 (da) Virus, der udtrykker et toksisk protein, og producercellelinier
KR920012445A (ko) 단백질을 이용한 발현벡터의 제조방법
DK1251173T3 (da) Secernerede og transmembrane polypeptider og nucleinsyrer kodende for disse
DK1217006T3 (da) Polypeptider og nucleinsyrer kodende for samme